

# ISPOR 2019

The professional society for health economics and outcomes research

May 18-22, 2019

*Rapid. Disruptive. Innovative:  
A New Era in HEOR*

## Program and Schedule of Events

 #ISPORAnnual


**NETWORK: ISPOR2019 / WI-FI PASSWORD: HEALTHCORE**

 ISPOR

[www.ispor.org](http://www.ispor.org)



# HEOR is changing at a rapid pace. Let ISPOR guide you through it.



**Join a global network of more than 20,000 healthcare professionals who are improving healthcare decisions**

**Members enjoy:**

- Admission to a global network of diverse healthcare stakeholders
- Access to healthcare's key influencers, from payers and providers to researchers and patients
- Discounts on event registrations
- Subscriptions to all ISPOR publications
- Special awards and recognition
- Exclusive online HEOR tools and cutting-edge science
- Knowledge-sharing opportunities with ISPOR colleagues

New to the field? Explore ISPOR member perks like private career development resources, members-only education and training programs, and exclusive networking opportunities!

**Take advantage of your  
ISPOR membership**  
[www.ispor.org/GetInvolved](http://www.ispor.org/GetInvolved)

# ISPOR 2019

May 18-22

*Rapid. Disruptive. Innovative:  
A New Era in HEOR*



## Table of Contents

<b>ISPOR 2019 AGENDA AT A GLANCE</b>	<b>4</b>
<b>CONFERENCE PROGRAM COMMITTEE</b>	<b>9</b>
<b>CONFERENCE SPONSORS</b>	<b>10</b>
<b>PLENARY SESSIONS</b>	<b>11</b>
<b>SCHEDULE OF EVENTS</b>	
● SATURDAY, MAY 18	14
● SUNDAY, MAY 19	17
● MONDAY, MAY 20	21
● TUESDAY, MAY 21	29
● WEDNESDAY, MAY 22	37
<b>INVITATIONAL GROUP MEETINGS</b>	<b>42</b>
<b>POSTER OVERVIEW</b>	<b>46</b>
<b>EXHIBIT PROGRAM OVERVIEW</b>	<b>47</b>
<b>EXHIBITOR LISTING</b>	<b>48</b>
<b>POSTER AND EXHIBIT HALL FLOOR PLAN</b>	<b>49</b>
<b>2019 ISPOR AWARDS PROGRAM</b>	<b>50</b>
<b>KEY INFORMATION</b>	<b>62</b>
<b>CONFERENCE ROOMS FLOOR PLAN</b>	<b>63</b>

# ISPOR 2019 Agenda-at-a-Glance

## Saturday, May 18, 2019

7:00AM - 7:00PM	REGISTRATION HELP DESK HOURS
8:00AM - 12:00PM	SHORT COURSE MORNING SESSION
8:00AM - 5:00PM	SHORT COURSE FULL DAY
1:00PM - 5:00PM	SHORT COURSE AFTERNOON SESSION
5:30PM - 6:30PM	EDUCATIONAL SYMPOSIUM

## Sunday, May 19, 2019

7:00AM - 7:00PM	REGISTRATION HELP DESK HOURS
8:00AM - 10:00PM	EXHIBITOR MOVE-IN
8:00AM - 12:00PM	SHORT COURSE MORNING SESSION
12:00PM - 6:00PM	SPEAKER READY ROOM HOURS
1:00PM - 5:00PM	SHORT COURSE AFTERNOON SESSION
5:00PM - 7:00PM	ISPOR STUDENT RESEARCH COMPETITION
5:30PM - 6:30PM	EDUCATIONAL SYMPOSIUM
6:30PM - 7:30PM	ISPOR PRESIDENTIAL RECEPTION (BY INVITATION ONLY)
7:00PM - 8:00PM	ISPOR STUDENT & FACULTY ICEBREAKER RECEPTION
7:30PM - 9:30PM	ISPOR INAUGURAL AWARDS BANQUET (PREREGISTRATION ONLY)

## Monday, May 20, 2019

7:00AM - 6:30PM	REGISTRATION HELP DESK HOURS
7:00AM - 8:15AM	ISPOR ASIA CONSORTIUM REGIONAL UPDATE
7:15AM - 8:15AM	EDUCATIONAL SYMPOSIUM
8:00AM - 6:00PM	SPEAKER READY ROOM HOURS
8:30AM - 10:30AM	<b>WELCOME &amp; FIRST PLENARY SESSION: THE DAWN OF DISRUPTION IN THE HEALTH SECTOR: WILL INNOVATIVE TECHNOLOGIES REQUIRE INNOVATIVE WAYS OF THINKING?</b>
10:30AM - 11:00AM	BREAK, POSTERS & EXHIBIT VIEWING
10:30AM - 11:30AM	ISPOR BOOTH EVENT— ENGAGE WITH THE ISPOR STUDENT NETWORK. MEET THE CHAIR: KOEN DEGELING
10:30AM - 2:00PM	RESEARCH POSTER PRESENTATIONS - SESSION 1
10:30AM - 7:30PM	POSTER & EXHIBIT HALL HOURS
11:00AM - 12:00PM	BREAKOUT SESSION 1
11:15AM - 11:45AM	EXHIBITOR HEOR THEATER
12:00PM - 1:30PM	LUNCH IN THE POSTER & EXHIBIT HALL



## Monday, May 20, 2019 continued

12:00PM – 2:00PM	BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION 1
12:15PM - 1:15PM	ISPOR BOOTH EVENT — NAVIGATE ISPOR'S EDUCATIONAL OFFERINGS WITH THE EDUCATION COUNCIL CHAIR: KAREN RASCATI, RPH, PHD
12:30PM - 1:30PM	EDUCATIONAL SYMPOSIUM
12:30PM – 1:45PM	ISPOR OPEN-SOURCE MODELS SPECIAL INTEREST GROUP: LIES, DAMNED LIES, AND COST-EFFECTIVENESS
12:30PM – 1:45PM	ISPOR REAL-WORLD EVIDENCE TRANSPARENCY COLLABORATIVE — THE CASE FOR STUDY REGISTRATION
12:30PM – 1:45PM	ISPOR ASIA CONSORTIUM-DRUG PRICING
12:30PM – 1:45PM	ISPOR ONCOLOGY SPECIAL INTEREST GROUP: IMPROVING THE AVAILABILITY AND QUALITY OF UTILITY ESTIMATES FOR THE POST-PROGRESSION PERIOD IN ONCOLOGY MODELS: RECOMMENDATIONS BASED ON A SYSTEMATIC REVIEW
12:30PM – 1:45PM	ISPOR HEALTH PREFERENCE METHODS SPECIAL INTEREST GROUP: FRONTIERS IN HEALTH PREFERENCE RESEARCH
12:30PM – 1:45PM	ISPOR LATIN AMERICA CONSORTIUM REGIONAL UPDATE
1:00PM - 2:00PM	POSTER AUTHOR DISCUSSION HOUR - SESSION 1
2:00PM - 3:00PM	ISPOR BOOTH EVENT — MAKE THE MOST OF YOUR ISPOR EXPERIENCE: UPDATE YOUR PROFILE AND ENTER TO WIN A MINI IPAD
2:15PM - 3:15PM	SPOTLIGHT SESSION — BACK TO THE FUTURE IN <i>VALUE IN HEALTH</i>
2:15PM - 3:15PM	SPOTLIGHT SESSION — BEYOND ONE SIZE FITS ALL: THE IMPORTANCE OF HETEROGENEITY IN PREFERENCE RESEARCH
2:15PM - 3:15PM	SPOTLIGHT SESSION — GLOBAL DEVELOPMENTS IN ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN HEALTHCARE
2:30PM - 3:00PM	EXHIBITOR HEOR THEATER
3:15PM - 3:45PM	BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION 2
3:15PM - 4:15PM	ISPOR BOOTH EVENT— GLOBAL NETWORKS: EXPLORE THE BENEFITS OF TRANSITIONING FROM CONFERENCE REGISTRANT TO MEMBER
3:30PM - 4:30PM	ISPOR STUDENT RESEARCH SPOTLIGHT
3:30PM - 7:00PM	RESEARCH POSTER PRESENTATIONS - SESSION 2
3:45PM - 4:45PM	BREAKOUT SESSION 2
4:00PM - 4:30PM	EXHIBITOR HEOR THEATER
5:00PM - 6:00PM	BREAKOUT SESSION 3
5:00PM – 6:00PM	ISPOR NEW PROFESSIONAL EVENT — CAREER ADVICE ACROSS THE GLOBE
6:00PM - 7:00PM	POSTER AUTHOR DISCUSSION HOUR - SESSION 2
6:00PM- 7:00PM	ISPOR BOOTH EVENT — <i>VALUE IN HEALTH'S</i> 20TH ANNIVERSARY CELEBRATION
6:00PM - 7:30PM	WELCOME RECEPTION IN THE EXHIBIT HALL
6:00PM - 9:00PM	“DINE-AROUND” WITH WOMEN IN HEOR (BY RESERVATION)
7:30PM - 9:00PM	ISPOR GLOBAL NETWORKS RECEPTION

# ISPOR 2019 Agenda-at-a-Glance continued

## Tuesday, May 21, 2019

7:00AM - 6:30PM	REGISTRATION HELP DESK HOURS
7:15AM - 8:15AM	EDUCATIONAL SYMPOSIUM
8:00AM - 6:00PM	SPEAKER READY ROOM HOURS
8:30AM - 10:30AM	<b>WELCOME &amp; SECOND PLENARY SESSION: MEDICAL DEVICE INNOVATION AND REGULATION: TURBOCHARGED FOR SUCCESS?</b>
10:30AM - 11:00AM	BREAK, POSTERS AND EXHIBIT VIEWING
10:30AM - 11:30AM	ISPOR BOOTH EVENT— ISPOR MEMBERSHIP: HOW TO GET MORE INVOLVED
10:30AM - 2:00PM	RESEARCH POSTER PRESENTATIONS - SESSION 3
10:30AM - 7:30PM	POSTER & EXHIBIT HALL HOURS
11:00AM - 12:00PM	BREAKOUT SESSION 4
11:15AM - 11:45AM	EXHIBITOR HEOR THEATER
12:00PM - 1:30PM	LUNCH IN THE POSTER & EXHIBIT HALL
12:00PM - 2:00PM	EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION 3
12:30PM - 1:30PM	EDUCATIONAL SYMPOSIUM
12:30PM - 1:45PM	ISPOR POLAND AND ISPOR UKRAINE CHAPTERS: NEW VALUE AND COVERAGE FOR INNOVATIVE MEDICINES IN CEE
12:30PM - 1:45PM	ISPOR PERSONALIZED PRECISION MEDICINE SPECIAL INTEREST GROUP: LEVERAGING REAL WORLD EVIDENCE TO ADDRESS UNCERTAINTY FOR TRANSFORMATIVE AND CURATIVE THERAPIES
12:30PM - 1:45PM	ISPOR REAL-WORLD EVIDENCE SPECIAL INTEREST GROUP
12:30PM - 1:45PM	ISPOR DIGITAL HEALTH SPECIAL INTEREST GROUP
12:30PM - 1:45PM	ISPOR PATIENT CENTERED SPECIAL INTEREST GROUP: HOW CAN HEALTH ECONOMICS AND OUTCOMES RESEARCHERS BE TORCHBEARERS FOR PATIENT ENGAGEMENT?
12:30PM - 1:45PM	ISPOR MEDICATION ADHERENCE AND PERSISTENCE SPECIAL INTEREST GROUP
1:00PM - 2:00PM	POSTER AUTHOR DISCUSSION HOUR - SESSION 3
1:00PM - 2:00PM	ISPOR GENERAL BUSINESS MEETING
2:15PM - 3:15PM	BREAKOUT SESSION 5
2:30PM - 3:00PM	EXHIBITOR HEOR THEATER
3:15PM - 3:45PM	BREAK & EXHIBITS VIEWING
3:30PM - 4:30PM	ISPOR BOOTH EVENT— TIPS AND ADVICE FOR NEW HEOR PROFESSIONALS: MEET THE CHAIR ELISABETH OEHRLEIN
3:30PM - 7:00PM	RESEARCH POSTER PRESENTATIONS - SESSION 4
3:45PM - 4:45PM	BREAKOUT SESSION 6
4:00PM - 4:30PM	EXHIBITOR HEOR THEATER

## Tuesday, May 21, 2019 continued

5:00PM - 6:00PM	BREAKOUT SESSION 7
5:00PM - 6:15PM	ISPOR WOMEN IN HEOR INITIATIVE: MENTORS AND THOUGHT LEADERSHIP: RELATIONSHIP BUILDING FOR CAREER SUCCESS
6:00PM - 7:00PM	POSTER AUTHOR DISCUSSION HOUR - SESSION 4
6:00PM - 7:30PM	NETWORKING RECEPTION IN THE EXHIBIT HALL
6:30PM - 7:30PM	ISPOR BOOTH EVENT — WOMEN IN HEOR NETWORKING RECEPTION

## Wednesday, May 22, 2019

7:00AM - 8:15AM	ISPOR HEALTH PREFERENCE METHODS SPECIAL INTEREST GROUP
7:15AM - 8:15AM	EDUCATIONAL SYMPOSIUM
8:00AM - 2:00PM	SPEAKER READY ROOM HOURS
8:00AM - 3:00PM	REGISTRATION HELP DESK HOURS
8:30AM - 9:30AM	BREAKOUT SESSION 8
9:30AM - 2:00PM	POSTER & EXHIBIT HALL HOURS
9:30AM - 2:00PM	RESEARCH POSTER PRESENTATIONS - SESSION 5
9:45AM - 10:45AM	PhRMA FOUNDATION SESSION/AWARDS
9:45AM - 10:45AM	BREAKOUT SESSION 9
10:00AM - 11:00AM	ISPOR BOOTH EVENT— TAKE CONTROL OF YOUR ISPOR EXPERIENCE: UPDATE YOUR MEMBER PROFILE AND EMAIL PREFERENCES
10:45AM - 11:00AM	BREAK, POSTERS & EXHIBIT VIEWING
11:00AM - 12:30PM	<b>WELCOME &amp; THIRD PLENARY SESSION: IS AFFORDABILITY DRIVING A NEED TO REVOLUTIONIZE DRUG PRICING?</b>
12:30PM - 1:45PM	EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION 5
12:30PM - 2:00PM	LUNCH IN THE POSTER & EXHIBIT HALL
12:45PM - 1:45PM	POSTER AUTHOR DISCUSSION HOUR - SESSION 5
2:00PM - 3:00PM	BREAKOUT SESSION 10

*\*Program subject to change. Please visit the conference website or refer to the mobile app for the most current information.*

## ISPOR 2019 Conferences



### ISPOR Latin America 2019

**12-14 September 2019 | Bogotá, Colombia**

*Data and Value in Healthcare: 2020 and Beyond*

Register by 30 July 2019 and save.



### ISPOR Summit 2019

**October 11, 2019 | Baltimore, MD, USA**



### ISPOR Europe 2019

**2-6 November 2019 | Copenhagen, Denmark**

Abstract Submission Closes: 12 June 2019

Register by 24 September 2019 and save.

## Upcoming Trainings

### Health Technology Assessment Training

**October 2019 | Beijing, China**

## Looking ahead to 2020 Conferences:

**ISPOR Regional  
2020  
Middle East**

**ISPOR 2020  
May 16-20, 2020  
Orlando, FL, USA**

Abstract Submission Opens:  
October 1, 2019

**ISPOR Asia Pacific 2020  
12-15 September 2020  
Seoul, South Korea**

Abstract Submission Opens:  
2 December 2019

**ISPOR Europe 2020  
14-18 November 2020  
Milan, Italy**

Abstract Submission Opens:  
2 March 2020

FOR MORE INFORMATION AND TO REGISTER: [www.ispor.org](http://www.ispor.org)




## Conference Program Committee

ISPOR thanks the Conference Program Committee for its contributions toward developing the scientific community's leading HEOR program.

---

### PROGRAM COMMITTEE CO-CHAIRS



**Jalpa Doshi, PhD**  
University of Pennsylvania,  
Philadelphia, PA, USA



**Brian O'Rourke, PharmD**  
CADTH, Ottawa, ON, Canada



**Rosanna Tarricone, PhD, MSc**  
Bocconi University, Milan, Italy

---

### ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS



**Jessica Daw, PharmD, MBA**  
UPMC Health Plan,  
Pittsburgh, PA, USA



**Hemant Phatak, PhD**  
EMD Serono, Inc.,  
Rockland, MA, USA



**Lotte Steuten, PhD, MSc**  
Office of Health Economics,  
London, UK

---

### RESEARCH COMMITTEE CO-CHAIRS



**Patrick Hopkinson**  
Bristol-Myers Squibb,  
Pharmaceuticals,  
Uxbridge, UK



**Lori McLeod, PhD**  
RTI Health Sciences,  
Research Triangle Park,  
NC, USA



**Ebere Onukwugha, MS, PhD**  
University of Maryland School  
of Pharmacy  
Baltimore, MD, USA



**Ya-Chen Tina Shih, PhD**  
University of Texas,  
MD Anderson  
Cancer Center,  
Houston, TX, USA

---

### WORKSHOP REVIEW COMMITTEE CO-CHAIRS



**Bruce Gingles**  
COOK Medical, Inc.,  
Bloomington, IN, USA



**K. Jack Ishak, PhD, MSc**  
Evidera, Montreal,  
QC, Canada



**Maureen Smith, MEd**  
CORD and PCORI,  
Ottawa, ON, Canada

## Thank You to Our Sponsors

---

### Gold Level Sponsors



---

### Silver Level Sponsors



---

### Bronze Level Sponsors



## Plenary Sessions



Kraft



Goodman



Caulfield



Chandler



Gee



Philip

### FIRST PLENARY SESSION: Monday, May 20, 8:30AM - 10:30AM

#### THE DAWN OF DISRUPTION IN THE HEALTH SECTOR: WILL INNOVATIVE TECHNOLOGIES REQUIRE INNOVATIVE WAYS OF THINKING?

The healthcare sector has recently witnessed several landmark moments in the development of the next generation of medical care. While media attention has rightly focused on milestone regulatory approvals for several groundbreaking curative treatments and devices, the best is likely yet to come: over 2600 clinical trials of gene therapies are either completed or ongoing; nearly 1000 trials of regenerative medicine are in progress worldwide; and more than 7000 trials for medical devices ranging from bionic eye brain implants to spinal cord stimulators are underway. Disruption will not be limited to drugs and devices. Advances in the applications of 3-D printing as well as artificial intelligence have the potential to generate powerful new tools for disease prevention, diagnosis, and treatment. In short, innovations that have long been the stuff of science fiction may no longer be distant points on the horizon. Are we entering a "golden age" of disruptive innovation in medical care? What new challenges and opportunities will these technologies bring? How can a health sector attuned to an old way of doing things truly prepare for treatments that break the mold? This plenary session will begin with an overview of the current and future landscape followed by a discussion among leading experts. Emerging challenges and opportunities presented by disruptive technologies will be addressed from the perspective of regulators, payers, manufacturers, providers, and patients.

**Keynote Speaker:** Daniel Kraft, MD, Singularity University and Exponential Medicine, Stanford, CA, USA

**Moderator:** Clifford Goodman, PhD, The Lewin Group, Falls Church, VA, USA

**Speakers:** Timothy Caulfield, LLM, University of Alberta, Edmonton, AB, Canada; Fleur Chandler, Duchenne, Twickenham, England; Rebekah E. Gee, MD, MPH, Louisiana Department of Health, Baton Rouge, LA, USA; Ron Philip, Spark Therapeutics, Inc., Philadelphia, PA, USA



Burke



Christopher



Coplan



Hull



Wijeyesundera

### SECOND PLENARY SESSION: Tuesday, May 21, 8:30AM - 10:30AM

#### MEDICAL DEVICE INNOVATION AND REGULATION: TURBOCHARGED FOR SUCCESS?

The medical implants market is one of the fastest-growing in healthcare. Yet alongside this rapid growth, the industry is facing increasing calls for regulation and oversight. As the demand for innovative medical devices accelerates, how can regulators ensure the highest level of health protection without hindering research and growth in the sector? This tension emerges from the two forces shaping the medical devices market: companies that are driving innovation, eager to bring needed new advances to patients and clinicians as quickly as possible and the regulators, responsible for governing the parameters of these advances. So how will the latest legislation fare? The new EU Medical Devices Regulation ([EU] 2017/745) will come into force on May 26, 2020 and is intended to "ensure a high level of safety and health while supporting innovation." Other regulators such as the FDA are also instituting major changes to their medical device regulations. How will these new regulations better guarantee patients' safety and strengthen confidence on the uptake and diffusion of medical devices? This plenary will explore how our healthcare systems navigate these controversies and identify implications and opportunities for the HEOR community, including the generation of relevant real-world evidence to support better decision making as well as what further regulations are needed. Finally, the panel will consider how such systems can evolve to keep up with the rapidly-innovating world of medical devices.

**Moderator:** Laurie Burke, MPH, LORA Group, LLC, Royal Oak, MD, USA

**Speaker:** Stephanie Christopher, MA, Medical Device Innovation Consortium, Washington, DC, USA; Paul Coplan, ScD, MBA, Johnson & Johnson, New Brunswick, NJ, USA; Stephen A. Hull, MHS, Hull Associates LLC, Rockland, MA, USA; Harindra Wijeyesundera, MD, PhD, CADTH, Ottawa, ON, Canada



Flood



Bhanji



Boysen



O'Brien



Trusheim

### THIRD PLENARY SESSION: Wednesday, May 22, 11:00AM - 12:30AM

#### IS AFFORDABILITY DRIVING A NEED TO REVOLUTIONIZE DRUG PRICING?

Promoting rapid and equitable access to promising therapies in an affordable manner is a laudable goal for all health systems. However, with the explosion of high cost, disruptive, and innovative drugs—many of which are promising a cure—payers are facing a crisis of affordability. We are in an era with six-figure cancer treatments, curative and costly gene therapies, ultra-high-cost drugs for treating orphan diseases, and even expensive drugs for more common diseases. It is an exciting and promising time for patients, clinicians, and pharmaceutical companies, and a challenging time for payers who must now look beyond cost-effectiveness to address affordability. The ISPOR 2019 Top 10 HEOR Trends report identified drug spending and pricing as the top trend. In the United States, President Trump launched his Blueprint to Lower Drug Prices in May 2018, and a recent paper from the University of Chicago reported that average total drug spending per hospital admission increased 18.5% between 2015 and 2017. Affordability of pharmaceuticals has become a truly global issue. Is it time for a revolution in how we price, fund, and manage drugs? Are there innovative approaches that can promote access, manage affordability, and still foster innovation? What can be done to significantly improve the transparency of drug prices? How do we ensure equitable access to low- and middle-income countries and disadvantaged populations?

**Moderator:** Colleen Flood, University of Ottawa Centre for Health Law, Policy and Ethics, Ottawa, ON, Canada

**Speakers:** Muna Bhanji, RPh, Merck, Philadelphia, PA, USA; Meindert Boysen, PharmD, MSc, NICE, Manchester, England; John M. O'Brien, PharmD, MPH, US Department of Health and Human Services, Washington, DC, USA; Mark Trusheim, MS, NEWDIGS and MIT, Boston, MA, USA

# Your ISPOR Conference App

## At your fingertips.

It's easy to personalize and maximize your ISPOR conference experience.



Search: ISPOR

NETWORK: **ISPOR2019**

WI-FI PASSWORD: **HEALTHCORE**

## Released Presentations

Looking for presentations from ISPOR 2019?

More than 85%  
of presentations  
will be available!

[www.ispor.org/ISPOR2019-Released-Presentations](http://www.ispor.org/ISPOR2019-Released-Presentations)

*Presentations are available online after each session, subject to speaker approval.*



# ISPOR 2019

May 18-22

*Rapid. Disruptive. Innovative:  
A New Era in HEOR*



## Program & Schedule of Events

● **Saturday** May 18

● **Sunday** May 19

● **Monday** May 20

● **Tuesday** May 21

● **Wednesday** May 22

**Pre-Conference Short Courses** are training courses offered across 7 HEOR key topic areas. The skill level ranges from introductory to advanced, and continuing education credits are available. *Separate registration is required.*

**Plenary Sessions** feature thought-provoking discussions on challenging topics related to healthcare policy, the application of HEOR in healthcare decision making, or methodology.

**Spotlight Sessions (SP)** highlight timely topics in HEOR and promote areas of innovation of interest to the ISPOR community.

**Issue Panels (IP)** introduce debates with multistakeholder perspectives on new or controversial issues in HEOR.

**Workshops (W)** discuss new and innovative applications in the conduct and use of HEOR or the latest on real-world data, clinical-, economic-, or patient-reported outcomes, patient-preferences, and healthcare policy.

**ISPOR Forums (F)** are presentations or facilitated discussions on current HEOR topics by ISPOR Member Groups (ie, Chapters, Networks, Consortia, Task Forces, Special Interest Groups, and Council Working Groups). Session content includes updates on regional issues and recent scientific research. Open to all attendees.

**Podium Presentations (P)** sessions consist of four 15-minute outcomes research presentations on a single topic.

**Poster Presentations** sessions contain approximately 350 research posters per session arranged by disease, topic, or healthcare intervention with a scheduled author discussion hour.

**Symposia** are sponsored presentations related to ISPOR's mission. The sponsor organization selects a subject of interest to delegates and arranges suitable speakers.

# Saturday May 18

7:00AM - 6:00PM **COAT ROOM HOURS** Hall H Lobby


7:00AM - 7:00PM **REGISTRATION HELP DESK HOURS** Hall H Lobby

7:00AM - 6:00PM **MULTI-FAITH PRAYER ROOM** Room 298 (2nd Floor)

7:00AM - 6:00PM **NURSING MOTHERS' ROOM** Room 299 (2nd Floor)

8:00AM - 5:00PM **SHORT COURSE FULL DAY** (Separate Registration Required)

**Introduction to Health Economics and Outcomes Research** Room 391 (3rd Floor)  
 Track: Economic Evaluation  
 Level: Introductory - This course is suitable for those with little or no experience with health economics.  
 Faculty: **Lorne Basskin, PharmD**, Charleston University, Charleston, WV, USA

 **Bayesian Analysis – Overview and Applications** Room 386 (3rd Floor)  
 Track: Methodological & Statistical Research  
 Level: Introductory - This course is designed for those with a limited understanding of Bayesian statistical concepts or for those who want a refresher and more practical experience.  
 Faculty: **Christopher S. Hollenbeak, PhD**, The Pennsylvania State University, Hershey, PA, USA; **David J. Vanness, PhD**, The Pennsylvania State University, Hershey, PA, USA


8:00AM - 12:00PM **SHORT COURSE MORNING SESSION** (Separate Registration Required)

**Introduction to the Design & Database Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources** Room 394 (3rd Floor)  
 Track: Study Approaches  
 Level: Introductory  
 Faculty: **Bradley Martin, PharmD, PhD, RPh**, University of Arkansas for Medical Sciences, Little Rock, AR, USA; **Benjamin M. Craig, PhD**, University of South Florida and Moffitt Cancer Center, Tampa, FL, USA

**Introduction to Modeling Methods** Room 395 (3rd Floor)  
 Track: Methodological & Statistical Research  
 Level: Introductory - This course is suitable for those with little experience with decision analysis, and is recommended as a pre-requisite to the ISPOR short courses, "Modeling: Design and Structure of a Model," "Bayesian Analysis," and "Advanced Decision Modeling for Health Economic Evaluations."  
 Faculty: **Mark S. Roberts, MD, MPP**, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA

**Introduction to Patient Reported Outcomes** Room 390 (3rd Floor)  
 Track: Patient-Centered Research  
 Level: Introductory - This course is intended for those with little experience with these methodologies.  
 Faculty: **Tara Symonds, PhD**, Clinical Outcomes Solutions, Folkestone, Kent, UK; **Alexandra I. Barsdorf, PhD**, Clinical Outcomes Solutions, Chicago, IL, USA; **Elizabeth (Nicki) Bush, MHS**, Eli Lilly and Company, Indianapolis, IN, USA

**Utility Measures** Room 387 (3rd Floor)  
 Track: Patient-Centered Research  
 Level: Introductory - No prior knowledge of utilities or health-related quality of life is assumed.  
 Faculty: **John E. Brazier, PhD, MSc**, University of Sheffield, Sheffield, UK; **Brendan Mulhern, MRes**, Senior Research Fellow, Health Economics and Outcomes Research, University of Technology Sydney, Sydney, Australia

 **New! Tools for Reproducible Real-World Data Analysis** Room 392 (3rd Floor)  
 Track: Real World Data & Information Systems  
 Level: Intermediate  
 Faculty: **Carrie Savage Bennette, MPH, PhD**, Flatiron Health, Seattle, WA, USA; **Blythe Adamson, PhD, MPH**, Flatiron Health, New York, NY, USA; **Joshua Kraut, MS**, Flatiron Health, Seattle, WA, USA

 Indicates hands-on exercises requiring the use of your personal computer.

# Saturday May 18


**Track:** Health Policy & Regulatory  
**Level:** Introductory - This course is designed for those with limited experience in the area of pharmaceutical pricing and covers topics within a global context.  
**Faculty:** **Jack M. Mycka**, Medical Marketing Economics LLC (MME), Montclair, NJ, USA; **Renato Dellamano, PhD**, MME Europe & ValueVector (Value Added Business Strategies), Milan, Italy

## 1:00PM - 5:00PM **SHORT COURSE AFTERNOON SESSION** (Separate Registration Required)

**Case Studies in Pharmaceutical/Biotech Pricing 2 – Advanced** Room 393 (3rd Floor)  
**Track:** Health Policy & Regulatory  
**Prerequisite:** Participation in the ISPOR short course, “Elements of Pharmaceutical/Biotech Pricing I – Introduction,” or equivalent knowledge, is required.  
**Level:** Intermediate - This course is designed for those with limited experience in the area of pharmaceutical pricing and covers topics within a global context.  
**Faculty:** **Jack M. Mycka**, Medical Marketing Economics LLC (MME), Montclair, NJ, USA; **Renato Dellamano, PhD**, MME Europe & ValueVector (Value Added Business Strategies), Milan, Italy

**Meta-Analysis and Systematic Reviews in Comparative Effectiveness Research** Room 395 (3rd Floor)  
**Track:** Study Approaches  
**Level:** Introductory - This course is designed for those having little experience with meta-analysis, or as a refresher and update for those with more experience.  
**Faculty:** **Joseph C. Cappelleri, PhD, MPH, MS**, Pfizer Inc, Groton, CT, USA; **Jeroen P. Jansen, PhD**, Precision Xtract, Oakland, CA, USA

**New!** **Health State Utility (HSU) Recommendations for Identification and Use of HSU Data in Cost-Effectiveness Modeling** Room 390 (3rd Floor)  
**Track:** Patient-Centered Research  
**Level:** Intermediate  
**Faculty:** **Andrew Lloyd, DPhil**, Acaster Lloyd Consulting Limited, London, UK; **John E. Brazier, PhD, MSc**, University of Sheffield, Sheffield, UK; **Jonathan Karnon, PhD**, Flinders University, Adelaide, Australia

 **Modeling: Design and Structure of a Model** Room 392 (3rd Floor)  
**Track:** Methodological & Statistical Research  
**Prerequisite:** Participation in the ISPOR short course “Introduction to Modeling Methods,” or equivalent knowledge, is required.  
**Level:** Intermediate - Participants should have a basic understanding of decision analysis.  
**Faculty:** **Shelby Corman, PharmD, MS**, Pharmerit International, Bethesda, MD, USA; **Mark S. Roberts, MD, MPP**, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA

**Applications in Using Large Databases** Room 396 (3rd Floor)  
**Track:** Study Approaches  
**Prerequisite:** Previous attendance at the ISPOR Short Course, “Introduction to Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources,” or equivalent knowledge, is recommended.  
**Level:** Intermediate - Participants must have some knowledge of administrative healthcare database analysis.  
**Faculty:** **Joanne LaFleur, PharmD, MPH**, George E. Whalen Veterans Health Administration IDEAS Center, Salt Lake City, UT, USA; **Brandon K. Bellows, PharmD, MS**, Columbia University, New York, NY, USA

**Use of Propensity Scores in Observational Studies of Treatment Effects** Room 394 (3rd Floor)  
**Track:** Study Approaches  
**Prerequisite:** Previous attendance at the ISPOR short course, “Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources,” or equivalent knowledge, is recommended.  
**Level:** Intermediate - This course is designed for those with little experience with this methodology, but have some knowledge of observational databases.  
**Faculty:** **John D. Seeger, PharmD, DrPH**, Optum, Waltham, MA, USA; **Jeremy A. Rassen, ScD**, Aetion, Inc., New York, NY, USA

**New!** **US Healthcare System and Its Approach to Value and Affordability™** Rooms 398-399 (3rd Floor)  
**Track:** Health Policy & Regulatory  
**Level:** Introductory - This course is designed for those having limited experience in understanding the structure of the US healthcare system, including its various subsystems and how they operate.  
**Faculty:** **James F. Murray, PhD**, Eli Lilly and Company, Carmel, IN, USA; **Laura T. Pizzi, PharmD, MPH, RPh**, Rutgers University, Piscataway, NJ, USA; **Karen Worley, PhD**, Humana, Cincinnati, OH, USA; **Finn Børlum Kristensen, MD, PhD**, University of Southern Denmark, Hilleroed, Denmark

## Saturday May 18

**Track:** Economic Evaluation  
**Prerequisite:** Participation in the ISPOR short course, "Introduction to Modeling Methods," or equivalent knowledge, is required.  
**Level:** Intermediate  
**Faculty:** **Jonathan D. Campbell, PhD**, University of Colorado Denver, Denver, CO, USA; **R. Brett McQueen, PhD**, University of Colorado Denver, Denver, CO, USA

**Value of Information: Active Learning, Modeling Tools and Applications** Room 387 (3rd Floor)

**5:30PM - 6:30PM EDUCATIONAL SYMPOSIUM** Rooms 383-385 (3rd Floor)

**AETION**

**De-Risking Risk Sharing: Enabling Payer-Pharma Interactions and Value-Based Contracting With RWE**

*Sponsored by: Aetion*

*Speakers:* **Sebastian Schneeweiss, MD, ScD**, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; **Jeremy Rassen, ScD**, Aetion, Inc., New York, NY, USA

 Indicates hands-on exercises requiring the use of your personal computer.

## Learn. Apply. Advance.

Learn from globally renowned leaders.  
 Apply knowledge to improve research methodologies.  
 Advance the science; advance your career.



Don't miss this opportunity to register for the premier educational program in health economics and outcomes research (HEOR). The ISPOR Short Course program offers engaging coursework—ranging from introductory to advanced—and hands-on learning to enhance attendees' knowledge and skills.

### Key advantages of ISPOR's Short Course programs:

- Learn from global leaders in the field of HEOR
- Develop your knowledge and skills through engaging coursework
- Review the latest research on best practices and best methods in HEOR
- Gain hands-on experience that translates into immediate, practical application
- Earn up to 16 CPE or CME credits (available at select conferences)

**Upcoming conference locations:** Bogotá, Colombia 2019; Copenhagen, Denmark 2019; Orlando, FL, USA 2020; Seoul, S. Korea 2020; Milan, Italy 2020

©2019 ISPOR – The professional society for health economics and outcomes research

**Come for the courses—  
stay for the conference!**

**Reserve your seat in the class today.**

Register for the Short Course program at  
[www.ispor.org](http://www.ispor.org)





# Sunday May 19

7:00AM - 6:00PM **COAT ROOM HOURS** Hall H Lobby

7:00AM - 7:00PM **REGISTRATION HELP DESK HOURS** Hall H Lobby

7:00AM - 8:00PM **MULTI-FAITH PRAYER ROOM** Room 298 (2nd Floor)

7:00AM - 8:00PM **NURSING MOTHERS' ROOM** Room 299 (2nd Floor)

8:00AM - 10:00PM **EXHIBITOR MOVE-IN** Poster and Exhibit Hall, Hall H

8:00AM - 12:00PM **SHORT COURSE MORNING SESSION** (Separate Registration Required)



**Using DICE Simulation for Health Economic Analyses** Room 392 (3rd Floor)

Track: Methodological & Statistical Research

Level: Introductory - This course is designed for those with some familiarity with modeling.

Faculty: **J. Jaime Caro, MDCM**, Evidera, Waltham, MA, USA and McGill University, Montreal, QC, Canada; **Jörgen Möller, MSc**, Evidera, Hammersmith, UK

**Cost-Effectiveness Analysis Alongside Clinical Trials** Room 387 (3rd Floor)

Track: Economic Evaluation

Level: Introductory - Familiarity with economic evaluations will be helpful.

Faculty: **Scott D. Ramsey, MD, PhD**, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA; **Richard J. Willke, PhD**, ISPOR, Lawrenceville, NJ, USA

**Statistical Methods in Economic Evaluations** Room 394 (3rd Floor)

Track: Economic Evaluation

Level: Intermediate - Participants should have basic knowledge of economic evaluations and statistics.

Faculty: **Shelby Reed, PhD, RPh**, Duke University, Durham, NC, USA; **Brad Hammill, DrPh, MS**, Duke University, Durham, NC, USA

**Risk Sharing/Performance-Based Arrangements for Drugs and Other Medical Products** Room 395 (3rd Floor)

Track: Health Policy & Regulatory

Prerequisite: It will be helpful for individuals to have completed the ISPOR short course, "Elements of Pharmaceutical/Biotech Pricing," or to be familiar with pharmaceutical pricing and the main international health systems.

Level: Intermediate

Faculty: **Louis P. Garrison, PhD**, University of Washington, Seattle, WA, USA; **Adrian Towse, MA, MPhil**, Office of Health Economics, London, UK; **Josh Carlson, MPH, PhD**, University of Washington, Seattle, WA, USA

**Stated Preference Methods – Part 1** Room 390 (3rd Floor)

Track: Patient-Centered Research

Level: Introductory

Faculty: **Brett Hauber, PhD**, RTI Health Solutions, Research Triangle Park, NC, USA; **Deborah Marshall, PhD**, University of Calgary, Calgary, AB, Canada; **John F. P. Bridges, PhD**, The Ohio State University College of Medicine, Columbus, OH, USA

**Advanced Patient-Reported Outcomes** Room 393 (3rd Floor)

Track: Patient-Centered Research

Level: Advanced

Faculty: **Cheryl Coon, PhD**, Outcometrix, Tucson, AZ, USA; **Jason Lundy, PhD**, Outcometrix, Tucson, AZ, USA



**Use of Instrumental Variables in Observational Studies of Treatment Effects** Room 386 (3rd Floor)

Track: Study Approaches

Prerequisite: Previous attendance at the ISPOR short course, "Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources," or equivalent knowledge, is recommended.

Level: Intermediate - This course is suitable for those with some knowledge of econometrics.


Faculty: **Benjamin M. Craig, PhD**, University of South Florida and Moffitt Cancer Center, Tampa, FL, USA; **Bradley Martin, PharmD, PhD, RPh**, University of Arkansas for Medical Sciences, Little Rock, AR, USA; **Antoine C. El Khoury, PhD, MS**, Janssen Pharmaceutical, Raritan, NJ, USA

Indicates hands-on exercises requiring the use of your personal computer.

# Sunday May 19

**Budget Impact Analysis 1 – A 6-Step Approach Room 391 (3rd Floor)**  
 Track: Economic Evaluation  
 Level: Intermediate - This course is designed for those with some experience with pharmacoeconomic analysis.  
 Faculty: **Josephine Mauskopf, PhD**, RTI Health Solutions, Research Triangle Park, NC, USA; **C. Daniel Mullins, PhD**, University of Maryland School of Pharmacy, Baltimore, MD, USA; **Stephanie R. Earnshaw, PhD, MS**, RTI Health Solutions, Research Triangle Park, NC, USA

**New! Market Access & Value Assessment of Medical Devices Rooms 388-389 (3rd Floor)**  
 Track: Health Policy & Regulatory  
 Level: Intermediate  
 Faculty: **Stephen A. Hull, MHS**, Hull Associates LLC, Rockland, MA, USA; **Michael Drummond, MCom, DPhil**, University of York, Heslington, York, UK; **Belinda A. Mohr, PhD**, W. L. Gore & Associates, Inc., Phoenix, AZ, USA; **Brian W. Bresnahan, PhD**, University of Washington and Harborview Medical Center, Seattle, WA, USA

 **Introduction to Health Technology Assessment Room 396 (3rd Floor)**  
 Track: Health Technology Assessment  
 Level: Introductory - This course is suitable for those with little or no experience with HTA.  
 Faculty: **Uwe Siebert, MPH, MSc, ScD, MD**, UMIT, Hall, Austria, and Massachusetts General Hospital, Boston, MA, USA

**12:00PM - 6:00PM SPEAKER READY ROOM Room 277 (2nd Floor)**

**1:00PM - 5:00PM SHORT COURSE AFTERNOON SESSION (Separate Registration Required)**

**Budget Impact Analysis 2 – Applications and Design Issues Room 392 (3rd Floor)**  
 Track: Economic Evaluation  
 Prerequisite: Participation in the ISPOR short course, "Budget Impact Analysis I: A 6-Step Approach," or equivalent knowledge, is recommended.  
 Level: Intermediate - This course is designed for those who have basic knowledge of budget impact analyses and desire exposure to these analyses in Excel.  
 Faculty: **Stephanie R. Earnshaw, PhD, MS**, RTI Health Solutions, Research Triangle Park, NC, USA; **Anita Brogan, PhD**, RTI Health Solutions, Manchester, LAN, UK; **Thor-Henrik Brodtkorb, PhD**, RTI Health Solutions, Ljungskile, Sweden

**Stated Preference Methods – Part 2 Room 390 (3rd Floor)**  
 Track: Patient-Centered Research  
 Level: Intermediate  
 Faculty: **Brett Hauber, PhD**, RTI Health Solutions, Research Triangle Park, NC, USA; **Deborah Marshall, PhD**, University of Calgary, Calgary, AB, Canada; **John F. P. Bridges, PhD**, The Ohio State University College of Medicine, Columbus, OH, USA

**Network Meta-Analysis Room 396 (3rd Floor)**  
 Track: Study Approaches  
 Level: Intermediate - This course requires at least a basic knowledge of meta-analysis and statistics.  
 Faculty: **Jeroen P Jansen, PhD**, Precision Xtract, Oakland, CA, USA; **Joseph C. Cappelleri, PhD, MPH, MS**, Pfizer Inc, Groton, CT, USA

**Advanced Decision Modeling for Health Economic Evaluations Room 391 (3rd Floor)**  
 Track: Methodological & Statistical Research  
 Prerequisite: Previous attendance at the ISPOR short course, "Modeling: Design and Structure of a Model," or equivalent knowledge, is required.  
 Level: Advanced - Participants should have an understanding of decision analysis.  
 Faculty: **Mark Sculpher, PhD**, University of York, York, UK; **Elisabeth Fenwick, PhD, MMA**, Pharmerit International, Oxford, UK

**Patient-Reported Outcomes: Item Response Theory Room 393 (3rd Floor)**  
 Track: Patient-Centered Research  
 Level: Intermediate - This course is designed for those with little to no experience with IRT.  
 Faculty: **Bryce B. Reeve, PhD**, Duke University, Durham, NC, USA

 Indicates hands-on exercises requiring the use of your personal computer.

# Sunday May 19

Track:	<b>Preference Data for Patient-Centric Benefit-Risk Analysis</b> Room 386 (3rd Floor)
Prerequisite:	Patient-Centered Research
Level:	Previous attendance at the ISPOR short course, "Conjoint Analysis – Theory and Methods," or equivalent knowledge of stated-preference methods, is required.
Faculty:	Advanced <b>F. Reed Johnson, PhD</b> , Duke Clinical Research Institute, Durham, NC, USA; <b>Bennett Levitan, MD, PhD</b> , Janssen Research & Development, LLC, Titusville, NJ, USA; <b>Juan Marcos Gonzalez Sepulveda, PhD</b> , Assistant Professor, Duke University, Durham, NC, USA
Track:	<b>A Health Economics Approach to US Value Assessment Frameworks</b> Rooms 388-389 (3rd Floor)
Level:	Health Technology Assessment
Faculty:	Introductory <b>Richard J. Willke, PhD</b> , ISPOR, Lawrenceville, NJ, USA; <b>Louis P. Garrison, PhD</b> , University of Washington, Seattle, WA, USA; <b>Charles E. Phelps, PhD, MBA</b> , University of Rochester, Gualala, CA, USA
Track:	<b>Causal Inference and Causal Diagrams in Big, Real-World Observational Data and Pragmatic Trials</b> Room 395 (3rd Floor)
Prerequisite:	Real-World Data & Information Systems
Level:	Previous attendance at the ISPOR short course, "Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources", or equivalent knowledge, is recommended.
Faculty:	Advanced <b>Uwe Siebert, MPH, MSc, ScD, MD</b> , UMIT, Hall, Austria, and Massachusetts General Hospital, Boston, MA, USA; <b>Douglas E. Faries, PhD</b> , Eli Lilly and Company, Indianapolis, IN, USA
5:00PM - 7:00PM	<b>ISPOR FORUMS</b> <b>ISPOR Student Research Competition</b> Rooms 278-280 (2nd Floor) The Student Research Competition, is a quiz competition featuring teams from ISPOR Student Chapters. Questions are from the ISPOR Book of Terms and ISPOR Good Research Practices for Outcomes Research. The top 3 winning teams receive a cash prize for their ISPOR Student Chapter. <i>Sponsored by ISPOR</i>
5:30PM - 6:30PM	<b>EDUCATIONAL SYMPOSIUM</b> Rooms 383-385 (3rd Floor) <b>Able to Cure, Able to Pay: Closing the Widening Gap</b> <i>Sponsored by: National Pharmaceutical Council</i> <i>Moderator: Robert W. Dubois, MD, PhD</i> , National Pharmaceutical Council, Washington, DC, USA <i>Speakers: Alexander Billioux, MD</i> , Louisiana Department of Health's Office of Public Health, Baton Rouge, LA, USA; <b>Vadim Lubarsky, MBA</b> , Novartis Services, Inc., Washington, DC, USA
6:30PM - 7:30PM	<b>ISPOR PRESIDENTIAL RECEPTION</b> (By invitation only) Hilton New Orleans Riverside
7:00PM - 8:00PM	<b>ISPOR STUDENT &amp; FACULTY ICEBREAKER RECEPTION</b> Room 281-282 (2nd Floor) All students and faculty are welcome to attend the reception where ISPOR will be distributing prizes and students, and faculty can network with their peers in a relaxed environment. The winning design for the t-shirt competition will be handed out to all students in advance. <i>Sponsored by Abbvie</i>
7:30PM - 9:30PM	<b>ISPOR INAUGURAL AWARDS BANQUET</b> (Separate preregistration required) Hilton New Orleans Riverside



# Unwrapping HEOR



For more than 20 years, readers have relied on *Value in Health* to deliver high-quality, scholarly articles that advance the field of health economics and outcomes research (HEOR). Each issue contains peer-reviewed, original research, and health policy articles that help healthcare leaders make evidence-based decisions that have a real-world impact on global populations and healthcare systems.

Later this year, the journal will unveil a new look for the publication—one that reflects the level of sophistication and prominence of the role HEOR is currently playing in improving healthcare decisions. Bold new look—same trusted content.

*Value in Health*... unwrapping the science of HEOR for readers around the world.

[www.ispor.org](http://www.ispor.org)

505 Lawrence Square Blvd South, Lawrenceville, NJ 08648  
© ISPOR – The professional society for health economics and outcomes research





# Monday May 20

7:00AM - 6:30PM **REGISTRATION HELP DESK HOURS** Hall H Lobby

7:00AM - 8:00PM **COAT ROOM HOURS** Hall H Lobby

7:00AM - 9:30PM **MULTI-FAITH PRAYER ROOM** Room 298 (2nd Floor)

7:00AM - 9:30PM **NURSING MOTHERS' ROOM** Room 299 (2nd Floor)

7:00AM - 8:15AM **ISPOR ASIA CONSORTIUM REGIONAL UPDATE** Room 292 (2nd Floor)

The ISPOR Asia Consortium is comprised of professionals interested in promoting health economics and outcomes research (HEOR) excellence to improve healthcare decision making in Asia Pacific and globally. The Asia Consortium provides a platform for information-sharing and institutional collaboration on HEOR and health policy, facilitating professional networking opportunities through scientific activities and global ISPOR initiatives. ISPOR Asia Consortium members include a diverse range of healthcare stakeholders, including payers and policymakers, regulators and assessors, clinicians and patients, researchers and industry. Currently we have over 1000 Asia Consortium members, and 31 Chapters in Asia Pacific with over 2000 Chapter members.

7:15AM - 8:15AM **EDUCATIONAL SYMPOSIUM** Rooms 278-282 (2nd Floor)



**21st Century FDA - Exploring the Rise of Real-World Evidence**

Sponsored by: Cardinal Health

Moderator: **Bruce A. Feinberg, DO**, Cardinal Health Specialty Solutions, Dublin, OH, USA

Speakers: **Jonathan Kish, PhD, MPH**, Cardinal Health Specialty Solutions, Dublin, OH, USA; **Annette Powers, PharmD, MBA**, Summit, NJ, USA; **Bhakti Arondekar, BPharm, MBA, PhD**, Pfizer Inc, Collegeville, PA, USA

8:00AM - 6:00PM **SPEAKER READY ROOM** Room 277 (2nd Floor)

8:30AM - 10:30AM **WELCOME & FIRST PLENARY SESSION** New Orleans Theater, Mid-Level Entrance

**Welcome from ISPOR CEO/Executive Director**

**Nancy S. Berg**, ISPOR, Lawrenceville, NJ, USA

**Presidential Address**

**Federico Augustovski, MD, MSc, PhD**, Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina

**Conference Program Overview from Program Committee Co-Chairs**

**Jalpa Doshi, PhD**, University of Pennsylvania, Philadelphia, PA, USA; **Brian O'Rourke, PharmD, CADTH**, Ottawa, ON, Canada; **Rosanna Tarricone, PhD, MSc**, Bocconi University, Milan, Italy

**2019 ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award**

**AWARDEE: Marc L. Berger, MD**, Consultant, New York, NY, USA

**FIRST PLENARY SESSION: THE DAWN OF DISRUPTION IN THE HEALTH SECTOR: WILL INNOVATIVE TECHNOLOGIES REQUIRE INNOVATIVE WAYS OF THINKING?**

**Keynote Speaker: Daniel Kraft, MD**, Singularity University and Exponential Medicine, Stanford, CA, USA

**Moderator: Clifford Goodman, PhD**, The Lewin Group, Falls Church, VA, USA

**Speakers: Timothy Caulfield, LLM**, University of Alberta, Edmonton, AB, Canada; **Fleur Chandler**, Duchenne, Twickenham, England; **Rebekah E. Gee, MD, MPH**, Louisiana Department of Health, Baton Rouge, LA, USA; **Ron Philip**, Spark Therapeutics, Inc., Philadelphia, PA, USA

10:30AM - 11:00AM **BREAK, POSTERS AND EXHIBIT VIEWING** Poster and Exhibit Hall, Hall H

10:30AM - 11:30AM **ISPOR BOOTH EVENT** Poster and Exhibit Hall, Booth #407

Engage with the ISPOR Student Network: Meet the Chair – Koen Degeling.

# Monday May 20

10:30AM - 2:00PM **RESEARCH POSTER PRESENTATIONS – SESSION 1** Poster and Exhibit Hall, Hall H

10:30AM - 7:30PM **POSTER AND EXHIBIT HALL HOURS** Poster and Exhibit Hall, Hall H

11:00AM - 12:00PM **BREAKOUT SESSION 1**

**IP1: The Controversial QALY: Is There a Middle Ground in the Debate?** New Orleans Theater, Mid-Level Entrance

Moderator: **Jennifer Bright, MPA**, Innovation and Value Initiative, Alexandria, VA, USA

Panelists: **Lou Garrison, PhD**, University of Washington, Seattle, WA, USA; **Eleanor M. Peretto, PhD, MS**, National Health Council, Washington, DC, USA; **Anna Kaltenboeck, MA**, Memorial Sloan Kettering Cancer Center, New York, NY, USA

**IP2: Replication of Randomized Controlled Trials Using Real-World Data: What Does Good Look Like?**

Rooms 393-394 (3rd Floor)

Moderator: **Marc Berger, MD**, Consultant, New York, NY, USA

Panelists: **David Martin, MD, MPH**, US Food and Drug Administration, Silver Spring, MD, USA; **Sebastian Schneeweiss, MD, ScD**, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; **David Thompson, PhD**, Syneos Health, Manchester, MA, USA

**IP3: Can Health Plans Address the Challenges to Accommodating the Growing Number of Orphan Drugs Entering the Marketplace?** Rooms 388-390 (3rd Floor)

Moderator: **James Chambers, PhD, MPharm, MSc**, Tufts Medical Center, Boston, MA, USA

Panelists: **Paul Melmeyer, MPP**, National Organization for Rare Disorders (NORD), Washington, DC, USA; **Susan A. Cantrell, CAE**, Academy of Managed Care Pharmacy, Alexandria, VA, USA; **Chris L. Pashos, PhD**, Abbvie, Cambridge, MA, USA

☀ **W1: Early Prediction of Survival Outcomes–Modeling Approaches for Translation of Tumor Response to Long-Term Clinical Benefits in Early Stage Cancer** Rooms 278-282 (2nd floor)

Discussion Leaders: **Andrew Briggs, DPhil**, University of Glasgow, Glasgow, Scotland, UK; **Min Huang, PhD**, Merck & Co., Inc., North Wales, PA, USA; **Jing Zhao, PhD**, Merck & Co., Inc., North Wales, PA, USA; **Scott D. Ramsey, MD, PhD**, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA

**W2: An Analytic Approach to Incorporating Patient Preferences into Value Elements for Economic Evaluation**

Rooms 395-396 (3rd Floor)

Discussion Leaders: **Susan dosReis, PhD**, University of Maryland School of Pharmacy, Baltimore, MD, USA; **Julia F. Slejko, PhD**, University of Maryland School of Pharmacy, Baltimore, MD, USA; **Darius N. Lakdawalla, PhD**, University of Southern California, Los Angeles, CA, USA; **Richard J. Willke, PhD**, ISPOR, Lawrenceville, NJ, USA

**P1: Artificial Intelligence Studies** Rooms 391-392 (3rd Floor)

11:00 - 11:15 **A11 An Innovative Artificial Intelligence Application in Disease Screening: An Opportunity to Improve Maternal Healthcare in an Underdeveloped Rural Area**

Shen JY<sup>1</sup>, Chen JB<sup>2</sup>, Liu ZR<sup>3</sup>, Song J<sup>3</sup>, Wong SY<sup>1</sup>, Wang XL<sup>4</sup>, Sui MG<sup>5</sup>, Magodoro I<sup>6</sup>, Akinwunmi B<sup>7</sup>, Zhang C<sup>8</sup>, Liu Q<sup>4</sup>, **Ming WK**<sup>9</sup>  
<sup>1</sup>School of Medicine, Jinan University, Guangzhou, China, <sup>2</sup>School of Information Science and Technology, Jinan University, Guangzhou, China, <sup>3</sup>School of International Studies, Sun Yet-sen University, Guangzhou, China, <sup>4</sup>School of Journalism and Communication, Jinan University, Guangzhou, China, <sup>5</sup>School of Economics, Jinan University, Guangzhou, China, <sup>6</sup>Centre for Global Health, Massachusetts General Hospital, Boston, MA, USA, <sup>7</sup>Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, USA, <sup>8</sup>School of Public Health, The University of Hong Kong, Hongkong, China, <sup>9</sup>Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

11:15 - 11:30 **A12 Leveraging Machine-Assistance to Replicate a Systematic Review**

**Michelson M**<sup>1</sup>, Ross M<sup>1</sup>, Minton S<sup>2</sup>, <sup>1</sup>Evid Science, El Segundo, CA, USA, <sup>2</sup>Inferlink, El Segundo, CA, USA

11:30 - 11:45 **A13 Discriminative Ability of Commonly Used Indices to Predict Outcomes After Total Knee Replacement: A Comparison of Demographics, Provider Volume, ASA Score, Charlson, Elixhauser and Functional Comorbidity Index**  
 Huang Z<sup>1</sup>, **Ruppenkamp J**<sup>2</sup>, Krishnan D<sup>3</sup>, Holy CE<sup>1</sup>, <sup>1</sup>Johnson & Johnson, New Brunswick, NJ, USA, <sup>2</sup>Johnson & Johnson, Garner, NC, USA, <sup>3</sup>Mu-sigma, Bangalore, India

11:45 - 12:00 **A14 Economic Impact Analysis and Predictive Modeling Identifying Risk Factors for Opioid Use Disorder in Medicaid Managed Care Populations**

Jones J, **Gao W**, Keleti D, Chen Y, Mistry P, AmeriHealth Caritas, Philadelphia, PA, USA

☀ Indicates an advanced session.

# Monday May 20

## P2: Cardiovascular Studies Rooms 383-385 (3rd Floor)

- 11:00 - 11:15 **CV1 Assessment of the High Risk and Unmet Need in Patients with CAD and Type 2 Diabetes (ATHENA): US Healthcare Resource Use and Cost in the Diabetes Collaborative Registry**  
Wittbrodt E<sup>1</sup>, Bhalla N<sup>1</sup>, Andersson Sundell K<sup>2</sup>, **Hunt P<sup>3</sup>**, Mellstrom C<sup>2</sup>, Gao Q<sup>4</sup>, Dong L<sup>4</sup>, Cavender M<sup>5</sup>, Wong ND<sup>6</sup>, <sup>1</sup>AstraZeneca, Wilmington, DE, USA, <sup>2</sup>AstraZeneca, Molndal, Sweden, <sup>3</sup>AstraZeneca, Gaithersburg, MD, USA, <sup>4</sup>Baim Institute for Clinical Research, Boston, MA, USA, <sup>5</sup>University of North Carolina, Chapel Hill, NC, USA, <sup>6</sup>University of California, Irvine, CA, USA
- 11:15 - 11:30 **CV2 Adverse Reaction Signal Detection for Statins in Reginal Healthcare Database Using Tree-Based Scan Statistic Method**  
Li H<sup>1</sup>, Zhang L<sup>2</sup>, **Zhan S<sup>3</sup>**, <sup>1</sup>West China Second Hospital, Sichuan University, chengdu, 51, China, <sup>2</sup>West China Second Hospital, Sichuan University, Chengdu, China, <sup>3</sup>Peking University Health Science Center, Beijing, China
- 11:30 - 11:45 **CV3 Variations in Healthcare Resource Use and Expenditures By Age in Patients Under Age 65 Newly Diagnosed with Paroxysmal Supraventricular Tachycardia (PSVT) in the United States**  
**Sacks NC<sup>1</sup>**, Everson KA<sup>2</sup>, Cyr PL<sup>3</sup>, Emden M<sup>3</sup>, Preib M<sup>3</sup>, Wood DR<sup>4</sup>, Pokorney SD<sup>5</sup>, <sup>1</sup>Tufts University School of Medicine, Boston, MA, USA, <sup>2</sup>Precision Health Economics, Los Angeles, CA, USA, <sup>3</sup>Precision Xtract, Boston, MA, USA, <sup>4</sup>Milestone Pharmaceuticals, Inc., Saint-Laurent, QC, Canada, <sup>5</sup>Duke University School of Medicine, Durham, NC, USA
- 11:45 - 12:00 **CV4 Budget Impact of Changing Oral Anticoagulant Prescribing to Prevent Atrial-Fibrillation-Related Stroke in England**  
**Orlowski A<sup>1</sup>**, Wu JH<sup>2</sup>, Wilkins J<sup>1</sup>, Smith W<sup>1</sup>, <sup>1</sup>Imperial College Health Partners, London, UK, <sup>2</sup>University of Leeds, Leeds, UK

12:00PM - 1:30PM **LUNCH IN THE EXHIBIT HALL** Poster and Exhibit Hall, Hall H

12:00PM - 2:00PM **EXHIBITS AND POSTER PRESENTATIONS VIEWING – SESSION 1** Poster and Exhibit Hall, Hall H

12:15PM – 1:15PM **ISPOR BOOTH EVENT** Poster and Exhibit Hall, Booth #407  
Learn. Apply. Advance. Navigate ISPOR's Educational Offerings With the Education Council Chair—Karen Rascati, RPh, PhD.

12:30PM - 1:30PM **EDUCATIONAL SYMPOSIUM** New Orleans Theater, Mid-Level Entrance



### Challenges of Economic Modeling in Rare Diseases and Assessment of Value in SMA

Sponsored by: Biogen

Moderator: **Robin Thompson, PhD, MSc**, Biogen, Baar, Switzerland

Speakers: **Chris Knight, MSc**, RTI Health Solutions, Manchester, LAN, UK; **Kenneth Hobby, MBA**, Cure SMA, Elk Grove Village, IL, USA; **Mark Connolly, PhD**, Global Market Access Solutions, Mooresville, NC, USA

12:30PM - 1:45PM **ISPOR FORUMS**

### ISPOR Oncology Special Interest Group: Improving the Availability and Quality of Utility Estimates for the Post-Progression Period in Oncology Models: Recommendations Based on a Systematic Review Rooms 388-390 (3rd Floor)

The forum discusses a systematic review of utility estimates for the post-progression period for all oncology indications. The discussion leaders will present: 1. An overview of the methods and results: Out of a total of 4839 published articles and 176 HTAs in all oncology indications; 350 publications and 60 technology appraisals were included. Review included details on study type, utility measure, sample size, number and timing of assessments, quality assessments, potential biases, utility estimates of caregivers/family members, and approaches to modeling post-progression period. Challenges/opportunities for collecting high quality utility data post-progression in RCTs and observational studies, including insights from an oncologist and ASCO member. Some “good practice” examples, and recommendations for future studies. This forum will be of value for researchers interested in QOL research, health utility estimation, economic evaluation, and/or HTA in oncology indications. Participants are invited to contribute to the discussion and make suggestions for future research methods.

### ISPOR Health Preference Methods Special Interest Group: Frontiers in Health Preference Research Room 397 (3rd Floor)

This forum will share a selection of novel methods and applications in health preference research. Preference methods increasingly are being used to collect evidence on preferences for treatment outcomes, health states, and health policies. The tools available to generate and analyze preference data have been advancing rapidly and this forum is intended to share such advances with ISPOR members. In this forum, the leadership of the Health Preference Research Special Interest Group selected studies that are novel because of how they were conceived, how they were implemented, or the way the resulting

# Monday May 20

data were analyzed. The forum will give expert preference researchers the opportunity to describe their work and how it contributes to the science of health preference research or to the implementation of the results in healthcare. After the presentations are concluded, the presenters will have an informal discussion with attendees as they enjoy lunch.

## **ISPOR Latin America Consortium Regional Update** *Room 292 (2nd Floor)*

Latin American delegates are encouraged to stop by and take the opportunity to meet with colleagues from the Latin America Consortium and discuss working committees and chapter updates, learn more about ISPOR Latin America 2019 in Bogotá, Colombia, follow up on the latest developments in HEOR and Health Policy from the region or talk to the Latin America team that will be available onsite for questions.

## **ISPOR Open-Source Models Special Interest Group: Lies, Damned Lies, and Cost-Effectiveness**

*Rooms 391-392 (3rd Floor)*

Cost-effectiveness and disease models are often statistically sophisticated and may be seen as opaque by stakeholders. Open-source models (OSM) would encourage greater transparency and facilitate the reuse and updating of the best/most useful models. Per ISPOR-SMDM and EUnetHTA, OSM will advance modeling methods by reducing bias, increasing transparency, improving model access, and allowing for faster access to critical knowledge. With openness and sharing come issues of copyright and access and a need to define how model sharing can be achieved in an equitable manner. The pros and cons of OSMs and the proposed mission of the Open Source Model SIG will be debated amongst SIG members.

## **ISPOR Real-World Evidence Transparency Collaborative – The Case for Study Registration** *Rooms 393-394 (3rd Floor)*

Real-world data (RWD) and real-world evidence (RWE) are becoming more accepted as ways to generate evidence for decision making. However, there are still questions about the quality and statistical rigor of the evidence provided by observational secondary studies. One way to help determine the quality of these types of studies is to have more transparency of the hypothesis and methods used to collate and analyze the data. This forum will present the current efforts of an ISPOR-led collaborative intending to move the needle on observational secondary study registration as a means to increase transparency. The progress and deliberations of this collaborative will be reviewed and discussed here, including concrete recommendations for next steps which will form the basis of a whitepaper. Feedback from the audience will be encouraged and collected to help inform the collaborative as it moves forward.

## **ISPOR Asia Consortium – Drug Pricing** *Rooms 395-396 (3rd Floor)*

Drug pricing is a complex issue and cost concerns affect the choices patients make about their care and lead to non-adherence. Value-based drug pricing and innovative negotiation agreement between the government and industry is a promising strategy to help improve patient outcomes at an affordable cost. How does the drug-pricing system change along with universal and value-driven coverage? How do we address rising drug costs while ensuring meaningful access to high-value care? In this session, our experts from Asia and beyond will address key issues surrounding drug pricing in their countries, such as main drivers of high drug-prices, drug pricing policies, the process of drug price negotiation, inherent challenges for various stakeholders, and possible solutions to form valued-based fair drug prices.

1:00PM - 2:00PM **POSTER AUTHOR DISCUSSION HOUR—SESSION 1** *Poster and Exhibit Hall, Hall H*

2:00PM - 3:00PM **ISPOR BOOTH EVENT** *Poster and Exhibit Hall, Booth #407*  
Make the Most of Your ISPOR Experience: Update Your Profile and Enter to Win a Mini iPad

2:15PM - 3:15PM **SPOTLIGHT SESSION**

### **SP1: Global Developments in Artificial Intelligence and Machine Learning in Health Care** *Rooms 278-282 (2nd floor)*

*Moderator: William Crown, PhD, Optum Labs, Cambridge, MA, USA*

*Speakers: Pall Jonsson, PhD, National Institute for Health and Care Excellence, London, England; Kurt D. Christensen, PhD, Brigham and Women's Hospital, Boston, MA, USA; Hidde Hovenkamp, MSc, Pacmed, Amsterdam, The Netherlands*

### **SP2: Back To The Future In Value In Health** *Rooms 395-396 (3rd Floor)*

*Moderator: Michael Drummond, PhD, University of York, York, England*

*Panelists: C. Daniel Mullins, PhD, University of Maryland, Baltimore, MD, USA; Joel Hay, PhD, USC School of Pharmacy, Los Angeles, CA, USA; Josephine Mauskopf, PhD, RTI Health Solutions, Durham, NC, USA*

### ★ **SP3: Beyond One Size Fits All: The Importance of Heterogeneity in Preference Research** *Rooms 393-394 (3rd Floor)*

*Discussion Leaders: Kevin Marsh, PhD, Evidera Ltd, Newport Pagell, BKM, UK; Martin Ho, MS, US Food and Drug Administration, Silver Spring, MD, USA; Juan Marcos Gonzalez Sepulveda, PhD, Duke University, Durham, NC, USA; Sebastian Heidenreich, PhD, Evidera, Aberdeen, UK*

# Monday May 20

3:15PM - 3:45PM **BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION 2** *Poster and Exhibit Hall, Hall H*

3:15PM - 4:15PM **ISPOR BOOTH EVENT** *Poster and Exhibit Hall, Booth #407*  
Global Networks: Explore the Benefits of Transitioning From Conference Registrant to Member

3:30PM - 4:30PM **ISPOR FORUMS** *Room 397 (3rd Floor)*

## ISPOR Student Research Spotlight

This revamp of the Student Research Showcase will allow for increased participation and interaction as it will feature 8 of the top-scored student outcomes research studies submitted for the conference. Attendees of the event will rotate to each presenter and listen to a 3- to 5-minute elevator pitch of the summary of the research study, the methods, challenges, the so what, conclusions, and the relevance of the research to the conference theme of Rapid. Disruptive. Innovative: A New Era in HEOR. Student Network Advisor, Zeba Khan and Faculty Advisor Council Chair, Laura Pizzi will serve as moderators and provide their feedback for each presenter.

3:30PM - 7:00PM **RESEARCH POSTER PRESENTATIONS – SESSION 2** *Poster and Exhibit Hall, Hall H*

3:45PM - 4:45PM **BREAKOUT SESSION 2**

## IP4: Proactive Post-Market Surveillance, 510(K) Update, and Real-World Evidence: Can It Improve Patient Safety, Outcomes and Provide a Competitive Edge? *Rooms 278-282 (2nd Floor)*

*Moderator:* Jill E. Sackman, DVM, PhD, Exponent, Farmington Hills, MI, USA

*Panelists:* Jessica Shepherd, MD, MBA, Baylor University Medical Center, Dallas, TX, USA; Colleen Riley, OD, Stryker, Mahwah, NJ, USA; Lori G. Cohen, JD, Greenberg Traurig, LLP, Atlanta, GA, USA

## IP5: Are Novel Concepts of Value Ready for Prime Time? *Rooms 395-396 (3rd Floor)*

*Moderator:* Jeroen P. Jansen, PhD, Innovation and Value Initiative, Los Angeles, CA, USA

*Panelists:* Darius N. Lakdawalla, PhD, University of Southern California, Los Angeles, CA, USA; Michael Drummond, MCom, DPhil, University of York, Heslington, York, UK; Sachin Kamal-Bahl, PhD, SKB Consulting Inc., Philadelphia, PA, USA

## IP6: The Clinical and Economic Value of Genetic Sequencing in Cancer Care: Are Next Generation Sequencing (NGS)-Based Tests Clinically Useful and Cost-Effective in Real-World Settings? What is Necessary to Fully Realize Their Value? *Rooms 388-390 (3rd Floor)*

*Moderator:* Lotte Steuten, PhD, MSc, Fred Hutchinson Institute for Cancer Outcomes, Seattle, WA, USA

*Panelists:* Sean R. Tunis, MD, MSc, Center for Medical Technology Policy, Baltimore, MD, USA; Neal Meropol, MD, Flatiron Health, New York, NY, USA; Daryl Pritchard, PhD, Personalized Medicine Coalition, Washington, DC, USA

## ★ W3: Using PFS to Determine the Cure Potential of New Innovative Therapies in DLBCL *Rooms 393-394 (3rd Floor)*

*Discussion Leaders:* Federico Felizzi, PhD, F. Hoffmann La Roche, Basel, Switzerland; Per-Olof Thuresson, MPharm, MSc, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Daniel Sheinson, PhD, Genentech, Inc., San Francisco, CA, USA; Anirban Basu, PhD, University of Washington, Seattle, WA, USA

## W4: Proactive: Linking Design, Analysis and Interpretation of PROs in Clinical Trials *Rooms 391-392 (3rd Floor)*

*Discussion Leaders:* Stephanie Manson, PhD, Novartis, East Hanover, NJ, USA; Donald Stull, PhD, Head, RTI Health Solutions, Research Triangle Park, NC, USA; Jessica K. Roydhouse, PhD, US Food and Drug Administration, Silver Spring, MD, USA; Pallavi Mishra-Kalyani, PhD, US Food and Drug Administration, Silver Spring, MD, USA

## P3: Modeling & Simulation Studies *Rooms 383-385 (3rd Floor)*

3:45 - 4:00 **MS1** A Comparison of Three and Four State Economic Models for Cost-Effectiveness Analysis in Oncology  
**Incerti D**, Jansen JP, Innovation and Value Initiative, Los Angeles, CA, USA

4:00 - 4:15 **MS2** An Updated Two-Year Survival Analysis of Axicabtagene Ciloleucel (AXI-CEL) in Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL)  
**Diakite I**<sup>1</sup>, Lin VW<sup>2</sup>, Klijn S<sup>3</sup>, Navale L<sup>2</sup>, Purdum AG<sup>2</sup>, Fenwick E<sup>4</sup>, Botteman M<sup>1</sup>, van Hout B<sup>5</sup>, <sup>1</sup>Pharmerit International, Bethesda, MD, USA, <sup>2</sup>Kite, A Gilead Company, Santa Monica, CA, USA, <sup>3</sup>Pharmerit International, Rotterdam, Netherlands, <sup>4</sup>Pharmerit International, Oxford, UK, <sup>5</sup>University of Sheffield, Sheffield, UK

4:15 - 4:30 **MS3** New Methodologies in Parametric Network Meta-Analyses (PNMA): Multi-Arm Correction for Random Effects and General Population Mortality (GPM)  
**van Beekhuizen S**<sup>1</sup>, van Oostrum I<sup>1</sup>, Ouwens DM<sup>2</sup>, Heeg B<sup>1</sup>, <sup>1</sup>Ingress-Health, Rotterdam, Netherlands, <sup>2</sup>AstraZeneca, Mölndal, Sweden

★ Indicates an advanced session.



# Monday May 20

4:30 - 4:45 **MS4 A Comparison of the Partitioned Survival and Multistate Extrapolation Methods: A Case Study Based on the Gastric Cancer Trial Attraction-2**  
**Klijn S<sup>1</sup>**, Bertwistle D<sup>2</sup>, Contente M<sup>3</sup>, Kroep S<sup>4</sup>, <sup>1</sup>Pharmerit International, Rotterdam, ZH, Netherlands, <sup>2</sup>Bristol-Myers Squibb, Uxbridge, Middlesex, UK, <sup>3</sup>Bristol-Myers Squibb Pharmaceuticals, Ltd, Uxbridge, LON, UK, <sup>4</sup>Pharmerit International, Rotterdam, Netherlands

## **P4: Rare & Orphan Diseases Studies Rooms 386-387 (3rd Floor)**

3:45 - 4:00 **RO1 Health-Related Quality of Life in Hereditary Transthyretin Amyloidosis: Qualitative Interviews with Patients**  
**Raymond K<sup>1</sup>**, Lovley A<sup>1</sup>, White MK<sup>1</sup>, Guthrie S<sup>2</sup>, Pollock M<sup>2</sup>, <sup>1</sup>Optum, Johnston, RI, USA, <sup>2</sup>Akcea Therapeutics, Boston, MA, USA

4:00 - 4:15 **RO2 Assessing the Relationship Between Lifelong Value and Pricing for Orphan Drugs in Ultra-Rare Diseases**  
**Dabbous O<sup>1</sup>**, Zhou ZY<sup>2</sup>, Tang C<sup>3</sup>, Harvey M<sup>2</sup>, Wu EQ<sup>4</sup>, Arjunji R<sup>1</sup>, <sup>1</sup>AveXis, Inc., Bannockburn, IL, USA, <sup>2</sup>Analysis Group, Inc., London, UK, <sup>3</sup>Analysis Group, Inc., New York, NY, USA, <sup>4</sup>Analysis Group, Inc., Boston, MA, USA

4:15 - 4:30 **RO3 Do Health Plans Cover Orphan and Non-Orphan Drugs Differently? An Empirical Analysis**  
**Margaretos N**, Panzer A, Neumann PJ, Chambers J, Tufts Medical Center, Boston, MA, USA

4:30 - 4:45 **RO4 Cost-Effectiveness Analysis of rFVIII-Fc, Pegylated rFVIII, and Eficizumab for the Prophylactic Treatment of Severe Hemophilia A Patients Without Inhibitors in the United States**  
 Li N<sup>1</sup>, **Bullement A<sup>2</sup>**, McMordie S<sup>2</sup>, Hatswell AJ<sup>2</sup>, Wilson K<sup>3</sup>, <sup>1</sup>Sanofi, Waltham, MA, USA, <sup>2</sup>Delta Hat, Nottingham, UK, <sup>3</sup>Swedish Orphan Biovitrum AB, Stockholm, Sweden

## **5:00PM - 6:00PM ISPOR FORUMS**

### **ISPOR New Professional Event: Career Advice Across the Globe Room 292 (2nd Floor)**

The New Professional Event, Career Advice Across the Globe, provides both New Professional and soon-to-graduate Student members with the opportunity to hear first-hand experiences from established ISPOR members around the world. Each conference focuses on a different career-related topic based largely from the results of our New Professional Interest Survey. This session's topic is: "Good Practices for HTA: What is Out There and How Can I Use it?"

## **5:00PM - 6:00PM BREAKOUT SESSION 3**

### **IP7: How Much Should We—and Can We—Pay for Gene Therapies? Rooms 278-282 (2nd Floor)**

**Moderator:** Jason Shafrin, PhD, Precision Health Economics, Los Angeles, CA, USA

**Panelists:** Anupam B. Jena, MD, PhD, Harvard Medical School, Boston, MA, USA; Jeremy Schafer, PharmD, MBA, Precision for Value, Chicago, IL, USA; Ramesh Arjunji, PhD, AveXis, Inc., Bannockburn, IL, USA

### **IP8: Can We Make Global Value Assessments More Flexible and Comprehensive? Rooms 388-390 (3rd Floor)**

**Moderator:** Peter J. Neumann, ScD, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

**Panelists:** Finn Børlum Kristensen, MD, PhD, University of Southern Denmark, Hilleroed, Denmark; Mark Sculpher, PhD, University of York, York, UK; Devin Incerti, PhD, Precision Health Economics, Los Angeles, CA, USA

### **IP9: Are Standard HTA Approaches to Cost-Effectiveness Modeling Appropriate for Tumor-Agnostic Oncology Products with Basket Trials? Rooms 391-392 (3rd Floor)**

**Moderator:** Stacey Kowal, MSc, IQVIA, Fairfax, VA, USA

**Panelists:** Richard Chapman, PhD, MS, Institute for Clinical and Economic Review, Boston, MA, USA; Alex Upton, MSc, Bayer, Reading, UK; John Watkins, PharmD, MPH, BCPS, Blue Cross, Bothell, WA, USA

### **★ W5: Quantitative Patient Preferences and Values With Limited Information: Lessons From the Non-Health Benefits-Transfer Literature Rooms 393-394 (3rd Floor)**

**Discussion Leaders:** F. Reed Johnson, PhD, Duke Clinical Research Institute, Durham, NC, USA; Juan Marcos Gonzalez Sepulveda, PhD, Duke University, Durham, NC, USA; Bjorn Bolinder, MBA, BSc, AstraZeneca, Gaithersburg, MD, USA

### **W6: Artificial Intelligence for Next Generation Epidemiology and Outcomes Research Rooms 395-396 (3rd Floor)**

**Discussion Leaders:** Craig S. Roberts, PharmD, MPA, MBA, Merck & Co., Inc., Kenilworth, NJ, USA; Benjamin Birnbaum, PhD, Flatiron Health, New York, NY, USA; Wanmei Ou, PhD, Merck & Co., Inc., Boston, MA, USA; Kun Huang, PhD, Indiana University and Regenstrief Institute, Indianapolis, IN, USA

★ Indicates an advanced session.

# Monday May 20

## P5: Adherence, Persistence and Compliance Studies Rooms 386-387 (3rd Floor)

- 5:00 - 5:15 **AD1 Treatment Experiences of Patients with Schizophrenia: Findings from a Qualitative Focus Group Study**  
**Bessonova L**<sup>1</sup>, Sajatovic M<sup>2</sup>, Saucier C<sup>3</sup>, Weiden PJ<sup>1</sup>, Carpenter-Conlin J<sup>1</sup>, O'Sullivan AK<sup>1</sup>, White MK<sup>3</sup>, Velligan DI<sup>4</sup>, <sup>1</sup>Alkermes, Inc., Waltham, MA, USA, <sup>2</sup>University Hospitals Cleveland Medical Center, Cleveland, OH, USA, <sup>3</sup>Optum, Johnston, RI, USA, <sup>4</sup>The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
- 5:15 - 5:30 **AD2 Examining the Association Between Provider Outreach and Patients' Statin Refill Behavior for Patients Within a Medicare Advantage with Prescription Drug (MAPD) Coverage Population**  
**Chikermane S**<sup>1</sup>, Nguyen MK<sup>2</sup>, Esse T<sup>3</sup>, Abughosh S<sup>1</sup>, <sup>1</sup>University of Houston, Houston, TX, USA, <sup>2</sup>CareAllies, Richmond, TX, USA, <sup>3</sup>CareAllies, Houston, TX, USA
- 5:30 - 5:45 **AD3 Food Insecure Cancer Survivors Are More Likely to Forgo or Delay Medical Care**  
**Mcdougall J**, Anderson J, Adler Jaffe S, Dailey Y, Meisner A, Sussman A, Guest D, Wiggins C, University of New Mexico, Albuquerque, NM, USA
- 5:45 - 6:00 **AD4 The Impact of Medicare Star Rating Adherence Measures on Medication Adherence for Targeted and Non-Targeted Medications**  
**Parekh N**<sup>1</sup>, Munshi K<sup>2</sup>, Hernandez I<sup>3</sup>, Gellad WF<sup>4</sup>, Henderson R<sup>2</sup>, Shrank WH<sup>5</sup>, <sup>1</sup>UPMC Center for High-Value Health Care, Pittsburgh, PA, USA, <sup>2</sup>Express Scripts, Memphis, TN, USA, <sup>3</sup>University of Pittsburgh, Pittsburgh, PA, USA, <sup>4</sup>Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA, <sup>5</sup>UPMC Insurance Services Division, Pittsburgh, PA, USA

## P6: Reimbursement and Access Policy Studies Rooms 383-385 (3rd Floor)

- 5:00 - 5:15 **RE1 The Impact of Patient Copay on Abandonment of Prescribed Antiepileptic Drug Treatment in a Pediatric Patient Population**  
**Mehta D**<sup>1</sup>, Davis M<sup>2</sup>, Epstein A<sup>2</sup>, Lee A<sup>1</sup>, <sup>1</sup>Sunovion Pharmaceuticals Inc., Marlborough, MA, USA, <sup>2</sup>Medicus Economics, LLC, Milton, MA, USA
- 5:15 - 5:30 **RE2 The Impact of Financial Access to Healthcare on Productivity Loss and Associated Out-of-Pocket Costs Among Cancer Survivors**  
Xiong X<sup>1</sup>, Wu J<sup>2</sup>, **Lu K**<sup>3</sup>, <sup>1</sup>China Pharmaceutical University, Nanjing, China, <sup>2</sup>Presbyterian College, Clinton, SC, USA, <sup>3</sup>University of South Carolina College of Pharmacy, Columbia, SC, USA
- 5:30 - 5:45 **RE3 At What Price Does CAM2038's Effectiveness Align with Value When Treating Opioid Use Disorder in the United States: A Cost-Utility Model**  
**Kumar VM**, Ellis A, Samur S, Chapman R, Institute for Clinical and Economic Review, Boston, MA, USA
- 5:45 - 6:00 **RE4 US Commercial Health Plans Cite International Health Technology Assessments in Their Specialty Drug Coverage Decisions with Different Frequencies**  
Shah V<sup>1</sup>, **Chambers J**<sup>2</sup>, Panzer A<sup>2</sup>, Margaretos N<sup>2</sup>, <sup>1</sup>University of Manchester, London, UK, <sup>2</sup>Tufts Medical Center, Boston, MA, USA

**6:00PM - 7:00PM ISPOR BOOTH EVENT** Poster and Exhibit Hall, Booth #407  
Value in Health's 20th Anniversary Celebration

**6:00PM - 7:00PM POSTER AUTHOR DISCUSSION HOUR - SESSION 2** Poster and Exhibit Hall, Hall H

**6:00PM - 7:30PM WELCOME RECEPTION IN THE EXHIBIT HALL** Poster and Exhibit Hall, Hall H  
Be sure to attend the official exhibit hall opening and welcome reception at ISPOR 2019. Greet old friends and colleagues, make new connections and take advantage of the chance to meet one-on-one with industry leaders who are available to discuss and review the latest innovative products in the health economics and outcomes research (HEOR) field. Over 100 exhibitors and sponsors will be present to help you discover solutions and discuss the trends in HEOR. In addition, there will be more than 350+ posters available for viewing during the reception. A live local Bourbon Street Band will get the party started along with complimentary wine, beer, soft drinks, and hors d'oeuvres. We look forward to greeting you at the welcome reception!

# Monday May 20

## 6:00PM – 9:00PM **"DINE-AROUND" WITH WOMEN IN HEOR** *Offsite*

Enjoy the perfect opportunity to sample some of New Orleans' delicious foods while engaging in conversations with your colleagues from the Women in Health Economics and Outcomes Research (HEOR) Initiative. We are offering dine-around options during the conference. This special dining option is limited to groups of no more than 10 attendees and features a variety of New Orleans' restaurants. Each group has a designated dinner host(s) who is coordinating the event at that restaurant venue. Participants will cover their own cocktails and dinner. Tables fill up quickly, so please be sure to visit the ISPOR Women in HEOR Initiative webpage (<https://www.ispor.org/strategic-initiatives/more/women-in-heor>) to reserve your seat!

## 7:30PM – 9:00PM **ISPOR GLOBAL NETWORKS RECEPTION** *New Orleans Theater Foyer, Mid-Level*

ISPOR invites you to a unique networking opportunity – an ISPOR Global Networks Reception! Meet with members of ISPOR Consortia in Asia, Latin America and Central and Eastern Europe, as well as ISPOR Networks in the Middle East and Africa, to exchange knowledge, share experiences, and learn about ISPOR global groups during this joint event. This reception is open to all meeting attendees interested in our Global Networks. Join us for this truly multicultural experience and connect with regional experts in health economics, learn how members of the ISPOR Global Networks benefit from and contribute to ISPOR, and find out how you can also get involved!



## ISPOR Career Center—*The Job Site for HEOR Professionals*

**Develop Your HEOR Career**

- Search and apply to the best jobs at organizations that value your credentials
- Upload your anonymous resume so employers can contact you discretely
- Receive job alerts that match your personal profile, skills, and interests
- Access career resources, such as resume-writing advice, resume reviews, and interview tips

**Recruit for Your Positions**

- Post your jobs where the most qualified HEOR professionals will find and apply to them
- Easily manage your posted jobs and applicant activity on our user-friendly site
- Email your jobs directly to job seekers via our exclusive Job Flash email
- Search the resume database and contact qualified candidates proactively

For more information, visit [www.ispor.org/careers](http://www.ispor.org/careers).



**ISPOR**  
Improving healthcare decisions

# Tuesday May 21

7:00AM - 6:30PM **REGISTRATION HELP DESK HOURS** Hall H Lobby

7:00AM - 8:00PM **COAT ROOM HOURS** Hall H Lobby

7:00AM - 8:00PM **MULTI-FAITH PRAYER ROOM** Room 298 (2nd Floor)

7:00AM - 8:00PM **NURSING MOTHERS' ROOM** Room 299 (2nd Floor)

7:15AM - 8:15AM **EDUCATIONAL SYMPOSIUM** Rooms 278-282 (2nd Floor)



**Concept to Coverage: Utilization of Value Assessment Frameworks in Payer Decision-Making**

Sponsored by: Xcenda

Moderator: **Kristen Migliaccio-Walle, BS**, Xcenda, Palm Harbor, FL, USA

Speakers: **Surya Singh, MD**, Sing Healthcare Advisors, Lexington, MA, USA; **Amir Bassiri, BA, MSW**, New York, NY, USA

8:00AM - 6:00PM **SPEAKER READY ROOM** Room 277 (2nd Floor)

8:30AM - 10:30AM **WELCOME & SECOND PLENARY SESSION** New Orleans Theater, Mid-Level Entrance

**Welcome from ISPOR President**

**Federico Augustovski, MD, MSc, PhD**, Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina

**Welcome from ISPOR Chief Science Officer**

**Richard J. Willke, PhD**, ISPOR, Lawrenceville, NJ, USA

**Incoming Presidential Address**

**Nancy Devlin, PhD**, University of Melbourne, Melbourne, Australia

**2019 ISPOR Marilyn Dix Smith Leadership Award**

**AWARDEE: Josephine Mauskopf, PhD**, RTI Health Solutions, Research Triangle Park, NC, USA

**SECOND PLENARY SESSION: MEDICAL DEVICE INNOVATION AND REGULATION: TURBOCHARGED FOR SUCCESS?**

Moderator: **Laurie Burke, MPH**, LORA Group, LLC, Royal Oak, MD, USA

Speakers: **Stephanie Christopher, MA**, Medical Device Innovation Consortium, Washington, DC, USA; **Paul Coplan, ScD, MBA**, Johnson & Johnson, New Brunswick, NJ, USA; **Stephen A. Hull, MHS**, Hull Associates LLC, Rockland, MA, USA; **Harindra Wijesundera, MD, PhD**, CADTH, Ottawa, ON, Canada

10:30AM - 11:00AM **BREAK, POSTERS AND EXHIBIT VIEWING** Poster and Exhibit Hall, Hall H

10:30AM - 11:30AM **ISPOR BOOTH EVENT** Poster and Exhibit Hall, Booth #407

ISPOR Membership: How to Get More Involved

10:30AM - 2:00PM **RESEARCH POSTER PRESENTATIONS – SESSION 3** Poster and Exhibit Hall, Hall H

10:30AM - 7:30PM **POSTER & EXHIBIT HALL HOURS** Poster and Exhibit Hall, Hall H

11:00AM - 12:00PM **BREAKOUT SESSION 4**

**IP10: The Rise of ICER Means the Loss of Choice: True, False or Uncertain?** Rooms 278-282 (2nd Floor)

Moderator: **Denise Kruzikas, PhD, MPH**, AESARA, Island Lake, IL, USA

Panelists: **Robert W. Dubois, MD, PhD**, National Pharmaceutical Council, Washington, DC, USA; **Michael Sherman, MD, MBA, MS**, Harvard Pilgrim HealthCare, Wellesley, MA, USA; **Ron Akehurst, DSc, Hon MFPHM**, BresMed Health Solutions, Sheffield, UK

**IP11: MCDA or Weighted CEA Based on the QALY? Which is the Future for HTA Decision Making?**

Rooms 388-390 (3rd Floor)

Moderator: **Nancy Devlin, PhD**, University of Melbourne, Melbourne, Australia

Panelists: **Charles Phelps, PhD**, University of Rochester, and Gualala, CA, USA; **Adrian Towse, MA, MPhil**, Office of Health Economics, London, UK

## Tuesday May 21

### **IP12: Controversies Around the Use of Patient-Reported Measures in Oncology: What Are the Benefits, Risks, and Barriers to Implementing PR-PMS in Value-Based Payment Programs?** Rooms 391-392 (3rd Floor)

*Moderator:* Theresa Schmidt, MA, Discern Health, Baltimore, MD, USA

*Panelists:* W. Garth Callaghan, Napkin Notes Dad, Glen Allen, VA, USA; Yousuf Zafar, MD, MHS, Duke Cancer Institute, Durham, NC, USA; Cynthia Grossman, PhD, Biogen, Cambridge, MA, USA

### **W7: How to Tackle the Estimation of Treatment Impact in the Presence of Differential Withdrawal and Missing Data Among Study Arms?** Rooms 393-394 (3rd Floor)

*Discussion Leaders:* Necdet Gunsoy, PhD, GlaxoSmithKline (GSK), Uxbridge, BKM, UK; Neil Hawkins, PhD, MSc, MBA, CStat, University of Glasgow, Scotland, UK; Helene Karcher, PhD, PAREXEL Access Consulting, London, UK

### **W8: Assessing the Value of Rare Disease Treatments: Global Lessons From Recent Case Studies**

Rooms 395-396 (3rd Floor)

*Discussion Leaders:* James Wu, MSc, MPH, Amgen, Thousand Oaks, CA, USA; Clifford Goodman, PhD, The Lewin Group, Falls Church, VA, USA; Louis P. Garrison, PhD, Strategic Pharmacy Innovations, Seattle, WA, USA; Paul Melmeyer, MPP, National Organization for Rare Disorders (NORD), Washington, DC, USA

### **P7: Clinical Outcomes Assessment Studies** Rooms 386-387 (3rd Floor)

11:00 - 11:15

#### **CL1** Defining and Demonstrating a Child-Caregiver Dyad Questionnaire Administration Approach to the Assessment of Pediatric Health-Related Quality of Life

Turner-Bowker D<sup>1</sup>, Yaworsky A<sup>1</sup>, Lamoureux R<sup>2</sup>, Kelly M<sup>1</sup>, Palladino A<sup>3</sup>, Love E<sup>1</sup>, Loftus J<sup>4</sup>, <sup>1</sup>Adelphi Values, Boston, MA, USA, <sup>2</sup>Adelphi Values, North Chelmsford, MA, USA, <sup>3</sup>Pfizer, Inc., Collegeville, PA, USA, <sup>4</sup>Pfizer Ltd, Tadworth, UK

11:15 - 11:30

#### **CL2** Identifying Symptoms Clusters Among Pediatric Kidney Disease Patients Using Promis® Computer Adaptive Tests

Peipert J, Chapman RS, Langer M, Cella D, Lai JS, Northwestern University, Chicago, IL, USA

11:30 - 11:45

#### **CL3** Understanding the Patient Voice in Comparative Effectiveness Studies: The Role of Benchmark Comparisons

Rendas-Baum R<sup>1</sup>, Laird B<sup>2</sup>, Rychlec K<sup>1</sup>, Brown JE<sup>2</sup>, Bayliss M<sup>1</sup>, <sup>1</sup>Optum Patient Insights, Johnston, RI, USA, <sup>2</sup>OptumRx, Minneapolis, MN, USA

11:45 - 12:00

#### **CL4** Minimal Clinically Important Difference: How International Patients View Pain, Distress and Treatment Outcomes

Du Y<sup>1</sup>, Jones SMW<sup>2</sup>, Bell-Brown A<sup>2</sup>, Unger JM<sup>2</sup>, <sup>1</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA, <sup>2</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA

### **P8: Medical Technology Studies** Rooms 383-385 (3rd Floor)

11:00 - 11:15

#### **MT1** Cost-Effectiveness of Robotic-Assisted Unicompartamental Knee Arthroplasty (R-UKA) Compared to Traditional Unicompartamental Knee Arthroplasty (T-UKA)

Nherera L, Verma S, Trueman P, Smith & Nephew, Hull, UK

11:15 - 11:30

#### **MT2** A Cost-Effectiveness Analysis of Posterior Facet Versus Pedicle Screw Fixation for Lumbar Spinal Fusion

Buttermann G<sup>1</sup>, Hollmann S<sup>2</sup>, Arpino JM<sup>2</sup>, Ferko N<sup>2</sup>, <sup>1</sup>Midwest Spine and Brain Institute, Stillwater, MN, USA, <sup>2</sup>Cornerstone Research Group Inc., Burlington, ON, Canada

11:30 - 11:45

#### **MT3** The Effectiveness of Capnography on Clinically Important Outcomes from Opioid-Induced Respiratory Depression: A Literature Review

Tilli T<sup>1</sup>, Baginska E<sup>2</sup>, <sup>1</sup>BD - Canada, Mississauga, ON, Canada, <sup>2</sup>BD - Canada, Mississauga, ON, Canada

11:45 - 12:00

#### **MT4** Cost Utility Analysis Update of Deep Brain Stimulation vs Best Medical Treatment in the Management of Parkinson Disease with Early Motor Complications in Colombia

Rueda M<sup>1</sup>, Arcos J<sup>2</sup>, Tellez J<sup>3</sup>, Valencia J<sup>4</sup>, <sup>1</sup>Clinica Soma, Medellin, Colombia, <sup>2</sup>Medtronic Colombia, Bogotá, Colombia, <sup>3</sup>Medtronic Colombia, Medellin, Colombia, <sup>4</sup>Medtronic, Miami, FL, USA

12:00PM - 1:30PM **LUNCH IN THE POSTER & EXHIBIT HALL** Poster and Exhibit Hall, Hall H

12:00PM - 2:00PM **EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION 3** Poster and Exhibit Hall, Hall H



# Tuesday May 21

## 12:30PM - 1:30PM **EDUCATIONAL SYMPOSIUM** Rooms 278-282 (2nd Floor)

### **ANALYSIS GROUP**

#### **Cell and Gene Therapy - Value and Access**

*Sponsored by: Analysis Group, Inc.*

**Moderator:** Michael Kuehn, RPh, MBA, GfK, New York, NY, USA

**Speakers:** Michael Sherman, MD, MBA, MS, Harvard Pilgrim HealthCare, Wellesley, MA, USA; Richard Chapman, PhD, MS, Institute for Clinical and Economic Review, Boston, MA, USA; Eric Q. Wu, PhD, Analysis Group, Inc., Boston, MA, USA; Hongbo Yang, PhD, Analysis Group, Inc., Boston, MA, USA

## 12:30PM - 1:45PM **ISPOR FORUMS**

### **ISPOR Digital Health Special Interest Group** Rooms 395-396 (3rd Floor)

One of challenges of the dramatic growth of digital health technologies is the lack of established and reliable methodological approaches to properly assess their value. We are forming the Digital Health Special Interest Group to create an opportunity for ISPOR members to address this and other topics in the field. Some of the digital health issues we will consider include: a universal definition; identifying the types and appropriateness of evidence currently used for evaluation; suggesting the best methods for future evaluations; and advancing health economic and outcomes research methods and promoting their use in health care decisions. During this presentation, attendees will have the opportunity to discuss topics and specific questions relating to digital health, as well as, to suggest additional ideas. The next steps for the SIG will be outlined. Grab your lunch and join us.

### **ISPOR Patient-Centered Special Interest Group: How Can Health Economics and Outcomes Researchers be Torchbearers for Patient Engagement?** Rooms 388-390 (3rd Floor)

ISPOR members interested in emerging approaches to patient engagement in research are welcome to attend this open discussion. Are you interested in how economics and outcomes researchers can prepare for a new era in HEOR in which patients are guiding research decisions? Grab your lunch and join us for a brief presentation on how patient engagement touches on various aspects of health economics and outcomes research and the value that is added from involving patients in this space. We will discuss the new ISPOR definition of "patient engagement in research," the revised special interest group structure, as well as identify core topics for the group to develop in the future. Attendees will have the opportunity to discuss and offer ideas on the core topics as well member engagement activities. All attendees are welcome.

### **ISPOR Medication Adherence and Persistence Special Interest Group** Rooms 383-385 (3rd Floor)

Attendees interested in the management of patients with multiple chronic conditions, the clinical and economical challenges associated with poly-pharmacotherapy, and medication adherence are welcome to attend this open discussion. Grab your lunch and join us for a brief presentation on the recently released systematic review on the methods for measuring multiple medication adherence and a proposed follow-up study. Discussion on the topics related to patients with multiple chronic conditions, such as how to evaluate adherence enhancing interventions and their influence on outcomes (eg, quality of life, clinical outcomes, patient satisfaction, resource utilization, etc.), given the limited evidence on how to assess the effects of these interventions along multiple criteria will be presented. Attendees will have the opportunity to discuss ideas for future projects for the special interest group to develop and opportunities for member engagement. All attendees are welcome.

### **ISPOR Real-World Evidence Special Interest Group** Rooms 393-394 (3rd Floor)

Increasingly, healthcare decision makers are looking for new opportunities that can help reduce the time required to bring health innovation to patients. Real-world evidence (RWE) is currently in the spotlight; however, regulators (amongst others) remain cautious as they evaluate how much they can trust RWE. We are forming a new RWE SIG dedicated to increasing awareness, understanding, and rigor and utilization of RWE as an important part of the wider evidence base for healthcare decision making. In order to be successful, ISPOR needs you, its members, to support this initiative, to address known and emerging challenges so that patients ultimately get access to the right treatment, at the right time. This open SIG meeting will present a range of RWE-specific topics to ascertain which concerns require immediate action, whether ISPOR is best placed to contribute to the solution, and to start defining how we collectively might address them. During the meeting, attendees will have the opportunity to contribute their perspectives, suggest alternative topics, and volunteer to help advance the future activities of the SIG.

### **ISPOR Personalized Precision Medicine Special Interest Group: Leveraging Real-World Evidence to Address Uncertainty for Transformative and Curative Therapies** Rooms 391-392 (3rd Floor)

Uncertainty around magnitude and duration of therapeutic effect has posed the fundamental value challenge for advanced gene- and cell-based therapies that promise transformative or curative effect. Real world evidence (RWE) is proposed as a core solution to bridge evidentiary uncertainty at all stages, ranging from regulatory to reimbursement and risk sharing. This panel will debate how and to what extent RWE approaches can be used to address uncertainty across the cell and gene therapy lifecycle. After an overview of evidence uncertainties associated with transformative therapies where RWE can address gaps is presented, we will explore how manufacturers are leveraging RWE approaches to demonstrate value and discuss the policy levers needed to integrate RWE at the regulatory and payer level. Lastly, we will highlight lessons from ongoing US work on transformative and curative therapies and recent initiatives.

# Tuesday May 21

## ISPOR Poland and ISPOR Ukraine Chapters: New Value and Coverage Frameworks for Innovative Medicines in CEE Rooms 386-387 (3rd Floor)

There is a need to define policy and criteria for making efficient resource allocation for financing of pharmaceuticals in Central and Eastern Europe. What best practices should be considered – multi-criteria decision analysis (MCDA) for innovative medicines, value-based pricing and value based procurement, managed entry agreements? Participants of this interactive Forum will discuss vision towards new trends and how to optimize access and value of innovative medicines in CEE. Interactive participation from the audience is anticipated.

1:00PM - 2:00PM **POSTER AUTHOR DISCUSSION HOUR – SESSION 3** Poster and Exhibit Hall, Hall H

1:00PM - 2:00PM **ISPOR GENERAL BUSINESS MEETING** Room 292 (2nd Floor)

Attendees are invited to attend ISPOR's General Business Meeting, the official business meeting of the Society. Members will learn about ISPOR's recent accomplishments and plans for the future, and have the opportunity to meet board members.

2:15PM - 3:15PM **BREAKOUT SESSION 5**

### IP13: To Register or Not to Register (The Protocol). That Is the Question in Observational and Big Data Studies, Economic Models, and Cost-Effectiveness Analysis. Rooms 278-282 (2nd Floor)

Moderator: **Federico Augustovski, MD, MSc, PhD**, University of Buenos Aires, Buenos Aires, Argentina

Panelists: **Rebecca J. Williams, PharmD, MPH**, National Institutes of Health, Bethesda, MD, USA; **Meindert Boysen, PharmD, MSc**, National Institute for Health and Care Excellence (NICE), Manchester, UK; **Peter J. Neumann, ScD**, Tufts Medical Center, Boston, MA, USA; **Marc Berger, MD**, Consultant, Inc, New York, NY, USA

### IP14: How Can New Outcomes Such as the Ones Derived from Wearables or Patient Experience Reports be Useful in Reimbursement and Coverage Decisions? Rooms 388-390 (3rd Floor)

Moderator: **Helene Karcher, PhD**, PAREXEL Access Consulting, London, UK

Panelists: **Katja Rudell, PhD**, Queen Mary University of London, Chittering, UK; **Stephane A. Regnier, MBA, PhD**, Novartis Pharma AG, Basel, Switzerland; **Sean R. Tunis, MD, MSc**, Center for Medical Technology Policy, Baltimore, MD, USA

### IP15: Single-Arm Trials of Novel Therapies. Too Good for Approval, but Not Good Enough for Reimbursement? Rooms 391-392 (3rd Floor)

Moderator: **Karissa M Johnston, PhD**, Memorial University, St. John's, NF, Canada

Panelists: **Catherine Davis, PharmD**, Bristol-Myers Squibb, Lawrenceville, NJ, USA; **Greta Lozano-Ortega, MSc**, Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada; **Sean D. Sullivan, PhD, MSc, RPh**, University of Washington, Seattle, WA, USA

### ★ W9: Use of Real-World Data to Extrapolate Survival Estimates for Cost-Effectiveness Analyses in Oncology Rooms 393-394 (3rd Floor)

Discussion Leaders: **C. Daniel Malone, PhD, RPh**, University of Arizona, Tucson, AZ, USA; **Federico Felizzi, PhD**, F. Hoffmann La Roche, Basel, Switzerland; **Ning Wu, PhD**, Genentech, Inc., San Francisco, CA, USA; **Daniel Sheinson, PhD**, Genentech, Inc., San Francisco, CA, USA

### W10: Developing Standard Core Sets of Clinical Outcome Assessments and Their Related Endpoints for Specific Disease Indications Rooms 395-396 (3rd Floor)

Discussion Leaders: **Meghana Chalasani, MHA**, US Food and Drug Administration, Silver Spring, MD, USA; **Laura Lee Johnson, PhD**, US Food and Drug Administration, Silver Spring, MD, USA; **Elektra Papadopoulos, MD, MPH**, US Food and Drug Administration, Silver Spring, MD, USA

### P9: Infectious Disease Studies Rooms 386-387 (3rd Floor)

2:15 - 2:30 **IN1 The Increased Risks of Non-Hepatic Cancers Among Hepatitis C Virus (HCV) Infected Patients: A Population-Based Cohort Study in the US**

**Wang W<sup>1</sup>**, Lo Re III V<sup>2</sup>, Guo Y<sup>3</sup>, Xiao H<sup>4</sup>, Brown J<sup>1</sup>, Park H<sup>1</sup>, <sup>1</sup>University of Florida, College of Pharmacy, Gainesville, FL, USA, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, USA, <sup>3</sup>University of Florida, College of Medicine, Gainesville, FL, USA, <sup>4</sup>Bristol-Myers Squibb, Lawrenceville, NJ, USA

2:30 - 2:45 **IN2 Temporal Changes in Cost-Effectiveness for Chronic Hepatitis C Virus Pharmacotherapy**

**Mattingly J<sup>1</sup>**, Love BL<sup>2</sup>, <sup>1</sup>University of Maryland School of Pharmacy, Baltimore, MD, USA, <sup>2</sup>University of South Carolina, Columbia, SC, USA

2:45 - 3:00 **IN3 One-Year Economic Burden Among Patients with Community-Acquired Pneumonia (CAP) Initially Managed in the Outpatient Setting: A Retrospective US Cohort Study, 2012-2017**

**Divino V<sup>1</sup>**, Schranz J<sup>2</sup>, Shah H<sup>3</sup>, Jiang M<sup>4</sup>, DeKoven M<sup>4</sup>, Zilberberg M<sup>5</sup>, <sup>1</sup>IQVIA, Fairfax, VA, USA, <sup>2</sup>Nabriva Therapeutics US, Inc., King of Prussia, PA, USA, <sup>3</sup>Value Matters, LLC, Ridgefield, CT, USA, <sup>4</sup>IQVIA, Falls Church, VA, USA, <sup>5</sup>EviMed Research Group, LLC, Goshen, MA, USA

## Tuesday May 21

- 3:00 - 3:15 **IN4 Reducing Hospital-Onset Clostridium Difficile Infection: An Agent-Based Modeling Approach to Evaluate Intervention Cost-Effectiveness**  
Barker A<sup>1</sup>, Scaria E<sup>1</sup>, Safdar N<sup>2</sup>, **Alagoz O**<sup>3</sup>, <sup>1</sup>University of Wisconsin, Madison, WI, USA, <sup>2</sup>William S. Middleton Memorial Veterans Hospital, Madison, WI, USA, <sup>3</sup>University of Wisconsin, Middleton, WI, USA
- 
- P10: Drug-Related Public Health Studies Rooms 383-385 (3rd Floor)**
- 2:15 - 2:30 **PH1 Risk of Pneumonia Due to Incident Antipsychotic Drug Use Among Parkinson's Disease Patients**  
**Inguva S**<sup>1</sup>, Yang Y<sup>2</sup>, Barnard M<sup>2</sup>, Pittman E<sup>2</sup>, <sup>1</sup>University of Mississippi, University, MS, USA, <sup>2</sup>University of Mississippi, University, MS, USA
- 2:30 - 2:45 **PH2 Dual-Trajectories of Opioid and Gabapentinoid Use and Risk of Subsequent Drug Overdose Among United States Medicare Beneficiaries**  
**Zhou L**<sup>1</sup>, Bhattacharjee S<sup>1</sup>, Kwok CK<sup>1</sup>, Tighe P<sup>2</sup>, Reisfield GM<sup>2</sup>, Malone D<sup>1</sup>, Slack M<sup>1</sup>, Lo-Ciganic W<sup>2</sup>, <sup>1</sup>University of Arizona, Tucson, AZ, USA, <sup>2</sup>University of Florida, Gainesville, FL, USA
- 2:45 - 3:00 **PH3 A Retrospective Database Analysis of Short-Acting and Long-Acting Opioid Use in Women with Endometriosis: I-Demographic Characteristics and Prevalence of Use**  
As-Sanie S<sup>1</sup>, **Soliman AM**<sup>2</sup>, Evans K<sup>3</sup>, Erpelding N<sup>4</sup>, Lanier R<sup>3</sup>, Katz N<sup>3</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MA, USA, <sup>2</sup>AbbVie, North Chicago, MA, USA, <sup>3</sup>Analgesic Solutions, LLC, Wayland, MA, USA, <sup>4</sup>Analgesic Solutions, LLC, Natick, MA, USA
- 3:00 - 3:15 **PH4 Association Between Polypharmacy and Health-Related Quality of Life Among Cancer Survivors in the United States**  
**Babcock Z**, Vyas A, Caffrey AR, Kogut S, University of Rhode Island, Kingston, RI, USA
- 
- 3:15PM - 3:45PM **BREAK AND EXHIBITS VIEWING Poster and Exhibit Hall, Hall H**
- 
- 3:30PM - 4:30PM **ISPOR BOOTH EVENT Poster and Exhibit Hall, Booth #407**  
Tips and Advice for New HEOR Professionals: Meet the Chair—Elisabeth Oehrlein
- 
- 3:30PM - 7:00PM **RESEARCH POSTER PRESENTATIONS – SESSION 4 Poster and Exhibit Hall, Hall H**
- 
- 3:45PM - 4:45PM **BREAKOUT SESSION 6**
- IP16: Real Option Value for Drugs: Is It Really an Option? Rooms 388-390 (3rd Floor)**  
Moderator: **Adrian Towse, MA, MPhil**, Office of Health Economics, London, UK  
Panelists: **Meng Li, PhD, ScM**, University of Southern California, Los Angeles, CA, USA; **Jens Grueger, PhD**, University of York, Heslington, York, UK
- IP17: Gene Therapy in Hemophilia: Can We Balance the Priorities of Patients, Providers, and Payers? Rooms 391-392 (3rd Floor)**  
Moderator: **Louis P. Garrison, PhD**, University of Washington, Seattle, WA, USA  
Panelists: **Jared Tate, PharmD**, Premera Blue Cross, Bothell, WA, USA; **Tim Brent, MBA**, Hemophilia Foundation, New York, NY, USA; **Richard McGee, MD**, True North Oncology Consultants, Edmonds, WA, USA
- IP18: Gazing into the HEOR Crystal Ball: What Might Be the Future Directions for HEOR in the 2020s? Rooms 278-282 (2nd Floor)**  
Moderator: **Finn Børlum Kristensen, MD, PhD**, University of Southern Denmark, Hilleroed, Denmark  
Panelists: **Nancy Devlin, PhD**, University of Melbourne, Melbourne, Australia; **Ross Maclean, MD, PhD, MBA**, Precision Health Economics, Los Angeles, CA, USA; **Andrew Briggs, DPhil**, University of Glasgow, Glasgow, Scotland, UK
- W11: Are We Capturing the Entire Picture? – Family Spillover Effects in Economic Evaluation Rooms 393-394 (3rd Floor)**  
Discussion Leaders: **Sachin Kamal-Bahl, PhD**, SKB Consulting Inc., Philadelphia, PA, USA; **Pei-Jung Lin, PhD**, Tufts Medical Center, Boston, MA, USA; **Erru Yang, MS**, Genentech, Inc., San Francisco, CA, USA; **Annie Kennedy, BS**, Parent Project Muscular Dystrophy, Hackensack, NJ, USA
- W12: Approaches to Advance the Value of Patient Preference Information in Medical Product Evaluation Rooms 395-396 (3rd Floor)**  
Discussion Leaders: **Anindita Saha, BSE**, US Food & Drug Administration, Silver Spring, MD, USA; **Heather Benz, PhD**, US Food and Drug Administration, Silver Spring, MD, USA; **Megan Moncur, MS**, US Food and Drug Administration, Silver Spring, MD, USA; **Laura Lee Johnson, PhD**, US Food and Drug Administration, Silver Spring, MD, USA

## Tuesday May 21

### P11: Comparative and Cost Analysis Rooms 386-387 (3rd Floor)

3:45 - 4:00

#### **CO1 A Cost-Utility Analysis of Degarelix in the Treatment of Prostate Cancer in China**

**Yang E<sup>1</sup>**, Du X<sup>1</sup>, Xuan J<sup>2</sup>, Fei J<sup>3</sup>, <sup>1</sup>Shanghai Centennial Scientific Ltd, Shanghai, China, <sup>2</sup>Sun Yat-Sen University, Guangzhou, China, <sup>3</sup>Ferring Pharmaceutical Consulting (Shanghai) Co., Ltd., Shanghai, China

4:00 - 4:15

#### **CO2 Using QALYS vs DALYS to Measure Cost-Effectiveness: Does it Matter?**

**Feng X**, Ollendorf DA, Kim DD, Cohen JT, Neumann PJ, Tufts Medical Center, Boston, MA, USA

4:15 - 4:30

#### **CO3 The Clinical and Economic Impact of HCV Treatment on Non-Hepatic Cancers Among HCV-Infected Patients**

**Wang W<sup>1</sup>**, Lo Re III V<sup>2</sup>, Guo Y<sup>3</sup>, Xiao H<sup>4</sup>, Brown J<sup>1</sup>, Park H<sup>1</sup>, <sup>1</sup>University of Florida, College of Pharmacy, Gainesville, FL, USA, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, USA, <sup>3</sup>University of Florida, College of Medicine, Gainesville, FL, USA, <sup>4</sup>Bristol-Myers Squibb, Lawrenceville, NJ, USA

4:30 - 4:45

#### **CO4 Alemtuzumab vs Generic Glatiramer Acetate 20mg in Patients with Relapsing Forms of Multiple Sclerosis: A Cost-Effectiveness Study in the United States**

**Chirikov V<sup>1</sup>**, Ma I<sup>2</sup>, Joshi N<sup>1</sup>, Patel D<sup>1</sup>, Smith A<sup>2</sup>, Giambrone C<sup>2</sup>, Cornelio N<sup>1</sup>, Greene N<sup>2</sup>, Hashemi L<sup>2</sup>, <sup>1</sup>Pharmerit International, Bethesda, MD, USA, <sup>2</sup>Sanofi, Cambridge, MA, USA

### P12: Real-World Data Studies Rooms 383-385 (3rd Floor)

3:45 - 4:00

#### **RW1 The Impact of Delaying ALK Inhibitor Therapy on Outcomes: A Prescription Time Matching Method**

**Sheinson D<sup>1</sup>**, Wu N<sup>2</sup>, Wong W<sup>2</sup>, <sup>1</sup>Genentech, Inc., San Francisco, CA, USA, <sup>2</sup>Genentech, Inc., South San Francisco, CA, USA

4:00 - 4:15

#### **RW2 Retrospective Real-World Assessment of Response Outcomes in Oncology**

**Espirito JL<sup>1</sup>**, Aguilar K<sup>1</sup>, Boyd M<sup>1</sup>, Frytak J<sup>1</sup>, Robert NJ<sup>2</sup>, <sup>1</sup>McKesson Life Sciences, The Woodlands, TX, USA, <sup>2</sup>McKesson Specialty Health, The Woodlands, TX, USA

4:15 - 4:30

#### **RW3 Framework for Reliable Value Assessment of Treatments Using Causal Analysis of Observational Data: Support Matching Biological Therapy to Rheumatoid Arthritis Patients**

**Shimoni Y<sup>1</sup>**, Ravid S<sup>2</sup>, Bak P<sup>3</sup>, Karavani E<sup>3</sup>, Hensley Alford S<sup>4</sup>, Meade D<sup>4</sup>, Goldschmidt Y<sup>3</sup>, <sup>1</sup>IBM Research - Haifa, Tel Aviv, TA, Israel, <sup>2</sup>IBM Research - Haifa, Givaatim, Israel, <sup>3</sup>IBM Research - Haifa, Haifa, Israel, <sup>4</sup>IBM Watson Health, Cambridge, MA, USA

4:30 - 4:45

#### **RW4 Development of Real-World Data and the Use of RWD for Evidence Generation in China**

**Cai B<sup>1</sup>**, Xie Y<sup>1</sup>, Gong Y<sup>1</sup>, Luo W<sup>1</sup>, Qu H<sup>2</sup>, Liu J<sup>1</sup>, <sup>1</sup>IQVIA, Shanghai, China, <sup>2</sup>IQVIA, Shanghai City, China

5:00PM - 6:00PM

### BREAKOUT SESSION 7

#### **IP19: How Should Data on Social Determinants of Health be Best Used to Improve Health Outcomes and Reduce Disparities? Rooms 388-390 (3rd Floor)**

**Moderator: Christie Teigland, PhD**, Avalere Health - An Inovalon Company, Bowie, MD, USA

**Panelists: Karl Kilgore, PhD**, Avalere Health - An Inovalon Company, Bowie, MD, USA; **Matthew Pickering, PharmD**, Pharmacy Quality Alliance, Alexandria, VA, USA; **Angela Hagan, MPA, PhD**, Humana, Inc., Willowick, OH, USA

#### **IP20: How Is the "Regulatory-Grade" Criterion Defined and What Does It Take for RWE to Meet it?**

**Rooms 278-282 (2nd Floor)**

**Moderator: David Thompson, PhD**, Syneos Health, Manchester, MA, USA

**Panelists: Dan Riskin, MD, MBA**, Verantos, San Francisco, CA, USA; **William H Crown, PhD**, OptumLabs, Cambridge, MA, USA; **David Martin, MD, MPH**, US Public Health Service; Center for Drug Evaluation and Research, Silver Spring, MD, USA

#### **W13: Leveraging Patient-Provided Information to Improve Real-World Evidence: Getting to Good Practices on How Rooms 395-396 (3rd Floor)**

**Discussion Leaders: Elisabeth Oehrlein, PhD, MS**, National Health Council, Washington, DC, USA; **Richard J. Willke, PhD**, ISPOR, Lawrenceville, NJ, USA; **Cristina Masseria, MSc, PhD**, Pfizer, New York, NY, USA; **Chris L. Pashos, PhD**, AbbVie US LLC, Chicago, IL, USA

#### **W14: Multicriteria Decision Analysis for Healthcare Decision Making in the United States: Active Learning Through a Real-Time MCDA Case Study Rooms 393-394 (3rd Floor)**

**Discussion Leaders: R. Brett McQueen, PhD**, University of Colorado Denver, Denver, CO, USA; **Jonathan D Campbell, PhD**, University of Colorado Denver, Aurora, CO, USA; **Zoltan Kalo, PhD**, Eötvös Loránd University, and Syreon Research Institute, Budapest, Hungary

## Tuesday May 21

### W15: Excel With Your Economic Models Using R Room 386-387 (3rd Floor)

Discussion Leaders: **Devin Incerti, PhD**, Precision Health Economics, Oakland, CA, USA; **Joseph Frank Levy, PhD**, Johns Hopkins University, Baltimore, MD, USA; **Jeroen P. Jansen, PhD**, Innovation and Value Initiative, Los Angeles, CA, USA

### P13: Oncology Studies Rooms 383-385 (3rd Floor)

5:00 - 5:15

#### ON1 Understanding Variation in Treatment Sequences and Outcomes in Metastatic Colorectal Cancer: Using Real-World Data to Answer Real-World Questions

Wong HL<sup>1</sup>, **Degeling K**<sup>2</sup>, Jalali A<sup>1</sup>, Shapiro J<sup>3</sup>, Kosmider S<sup>4</sup>, Wong R<sup>5</sup>, Lee B<sup>1</sup>, Burge M<sup>6</sup>, Tie J<sup>1</sup>, Yip D<sup>7</sup>, Nott L<sup>8</sup>, Khattak A<sup>9</sup>, Lim S<sup>10</sup>, Caird S<sup>11</sup>, Ijzerman M<sup>12</sup>, Gibbs P<sup>1</sup>, <sup>1</sup>Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia, <sup>2</sup>University of Twente, Enschede, Netherlands, <sup>3</sup>Cabrini Health, Malvern, VIC, Australia, <sup>4</sup>Western Health, Footscray, VIC, Australia, <sup>5</sup>Walter and Eliza Hall Institute of Medical Research, Box Hill, Australia, <sup>6</sup>Royal Brisbane and Women's Hospital, South Brisbane, QLD, Australia, <sup>7</sup>The Canberra Hospital, Garran, ACT, Australia, <sup>8</sup>Royal Hobart Hospital, Hobart, TAS, Australia, <sup>9</sup>Flora Stanley Hospital, Murdoch, Australia, <sup>10</sup>Campbelltown Hospital, Campbelltown, NSW, Australia, <sup>11</sup>Gold Coast University Hospital, Southport, QLD, Australia, <sup>12</sup>University of Melbourne, Melbourne, VIC, Australia

5:15 - 5:30

#### ON3 Impact of BRCA1/2 Mutation Status on Patient-Reported General Health Status in HER2-Advanced Breast Cancer: Results from a US Real-World Study

**Niyazov A**<sup>1</sup>, Lewis K<sup>2</sup>, Kemp J<sup>2</sup>, Rider A<sup>2</sup>, <sup>1</sup>Pfizer Inc., New York, NY, USA, <sup>2</sup>Adelphi Real World, Cheshire, UK

5:30 - 5:45

#### ON4 Review of the Application of Health-Related Quality of Life (HRQOL) Data in Recent Health Technology Assessments (HTAs) of Cancer Immunotherapies (IOS) By the National Institute for Health and Care Excellence (NICE)

**Bullement A**<sup>1</sup>, Shields G<sup>2</sup>, Hatswell AJ<sup>1</sup>, Schlichting M<sup>3</sup>, Bharmal M<sup>4</sup>, <sup>1</sup>Delta Hat Limited, Nottingham, UK, <sup>2</sup>University of Manchester, Manchester, UK, <sup>3</sup>Merck KGaA, Darmstadt, Germany, <sup>4</sup>Merck Healthcare KGaA, Darmstadt, Germany

### P14: Neurological Disorders Studies Room 292 (2nd Floor)

5:00 - 5:15

#### ND1 Experiences, Healthcare Needs, and Potential Patient-Centered Approaches to Treat Depression and Fatigue Among Individuals with Parkinson's Disease: A Focus Group Study

**Bhattacharjee S**<sup>1</sup>, Zhou L<sup>1</sup>, Yegezu Z<sup>2</sup>, Khalil M<sup>3</sup>, Sherman SJ<sup>4</sup>, <sup>1</sup>University of Arizona, Tucson, AZ, USA, <sup>2</sup>The University of Arizona, Tucson, AZ, USA, <sup>3</sup>West Virginia University, New York, NY, USA, <sup>4</sup>The University of Arizona, College of Medicine, Tucson, AZ, USA

5:15 - 5:30

#### ND2 Cost-Utility Analysis of Single Dose Gene-Replacement Therapy for Spinal Muscular Atrophy Type 1 Compared to Chronic Nusinersen Treatment

**Malone D**<sup>1</sup>, Dean R<sup>2</sup>, Miller B<sup>2</sup>, Arjunji R<sup>3</sup>, Feltner DE<sup>3</sup>, Sproule DM<sup>3</sup>, Jensen IS<sup>2</sup>, Maru B<sup>3</sup>, Dabbous O<sup>3</sup>, <sup>1</sup>University of Arizona, Tucson, AZ, USA, <sup>2</sup>Precision Xtract, Boston, MA, USA, <sup>3</sup>AveXis, Inc., Bannockburn, IL, USA

5:30 - 5:45

#### ND3 Use of Group-Based Trajectory Modeling to Identify Adherence Clusters in Patients with Multiple Sclerosis Newly-Initiating Once- or Twice-Daily Oral Disease-Modifying Drugs

**Nicholas J**<sup>1</sup>, Edwards NC<sup>2</sup>, Edwards RA<sup>2</sup>, Dellarole A<sup>3</sup>, Manca L<sup>3</sup>, Harlow DE<sup>4</sup>, Phillips A<sup>4</sup>, <sup>1</sup>OhioHealth Multiple Sclerosis Center, Columbus, OH, USA, <sup>2</sup>Health Services Consulting Corporation, Boxborough, MA, USA, <sup>3</sup>Fair Dynamics Consulting, Milan, Italy, <sup>4</sup>EMD Serono, Inc., Rockland, MA, USA

5:45 - 6:00

#### ND4 Comparison of Trinetx Electronic Medical Record Database and National Ambulatory Medical Care Survey: Findings on the Inappropriate Medications Use in Parkinson's Disease in the United States

**Masurkar P**<sup>1</sup>, Rege S<sup>2</sup>, Aparasu RR<sup>3</sup>, <sup>1</sup>College of Pharmacy, University of Houston, Houston, TX, USA, <sup>2</sup>Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USA, <sup>3</sup>University of Houston, Houston, TX, USA

### 5:00PM - 6:15PM ISPOR FORUMS

#### ISPOR Women in HEOR Initiative: Mentors and Thought Leadership: Relationship Building for Career Success Rooms 391-392 (3rd Floor)

This session is open to all attendees (women and men) interested in the advancement of women in the health economics and outcomes research (HEOR) field. The vision of the ISPOR Women in HEOR Initiative is to support the growth, development, and contribution of women in HEOR; to serve as a catalyst for women's leadership in the field; and to offer a platform for ISPOR women to collaborate, network, share, and mentor each other. We will outline the initiative's work to date, including results from a needs assessment survey and expand on growth opportunities including mentorship and networking with colleagues who seek to advance women's leadership in HEOR.

Speakers: **Renée Arnold, PharmD, RPh**, Icahn School of Medicine at Mount Sinai, and ICON PLC, New York, NY, USA; **Shelby Reed, PhD, RPh**, Duke University, Durham, NC, USA



## Tuesday May 21

6:00PM - 7:00PM **POSTER AUTHOR DISCUSSION HOUR – SESSION 4** *Poster and Exhibit Hall, Hall H*

6:00PM - 7:30PM **NETWORKING RECEPTION IN THE EXHIBIT HALL** *Poster and Exhibit Hall, Hall H*

After two full days of education sessions, learning opportunities, and scheduled meetings it is time to unwind and network! A New Orleans Jazz Quartet will provide the background music while you and your colleagues enjoy complimentary wine, beer, soft drinks and hors d'oeuvres. Take advantage of this dedicated time to visit the exhibitors you haven't had a chance to connect with, continue conversations with your colleagues, review posters, or just take advantage of the sponsored lounges to sit down, network and relax!

6:30PM - 7:30PM **ISPOR BOOTH EVENT** *Poster and Exhibit Hall, Booth #407*

**Women in HEOR Networking Reception**

Meet the speakers from the Women in HEOR open meeting and network with others who support the advancement of women in the field of HEOR.

## Media Partners



ISPOR thanks its media partners, *PM360* and *The American Journal of Managed Care*, for their help in promoting the **ISPOR 2019** conference to new audiences in the healthcare and health policy space.

For more information about our media partners, visit them online at [www.pm360online.com](http://www.pm360online.com) and [www.ajmc.com](http://www.ajmc.com).



[www.ispor.org](http://www.ispor.org)

# Wednesday May 22

7:00AM - 3:30PM **COAT ROOM HOURS** Hall H Lobby

8:00AM - 2:00PM **SPEAKER READY ROOM** Room 277 (2nd Floor)

8:00AM - 3:00PM **REGISTRATION HELP DESK HOURS** Hall H Lobby

8:00AM - 3:00PM **MULTI-FAITH PRAYER ROOM** Room 298 (2nd Floor)

8:00AM - 3:00PM **NURSING MOTHERS' ROOM** Room 299 (2nd Floor)

7:00AM - 8:15AM **ISPOR FORUMS** Room 292 (2nd Floor)

## ISPOR Health Preference Methods Special Interest Group

During the open meeting, participants will receive an update on the activities conducted by the SIG. These include the SIG business plan, the SIG member-engagement plan, and the new SIG project.

7:15AM - 8:15AM **EDUCATIONAL SYMPOSIUM** Rooms 278-282 (2nd Floor)



## The Evolution of HTAs: What Matters Most?

Sponsored by: Amgen

Moderator: **Anusha Kheir, MPH**, Amgen, Thousand Oaks, CA, USA

Speakers: **Louis P. Garrison, PhD**, University of Washington, Seattle, WA, USA; **Felicity McNeill, PSM**, Hepatitis Australia, Woden, ACT, Australia; **Gordon G. Liu, PhD**, Peking University, Beijing, China

8:30AM - 9:30AM **BREAKOUT SESSION 8**

## IP21: Replicable and Robust Database Evidence: What Does it Look like? Rooms 278-282 (2nd Floor)

Moderator: **Sebastian Schneeweiss, MD, ScD**, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

Panelists: **Shirley Wang, PhD**, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; **Kristijan Kahler, RPh, PhD**, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; **Laura Happe, PharmD, MPH**, Journal of Managed Care and Specialty Pharmacy, Alexandria, VA, USA

## IP22: How Can Biosimilars Make Headway in the USA? Dealing with the Legal, Regulatory, Payer Coverage Policy, and Access Challenges Rooms 388-390 (3rd Floor)

Moderator: **Anita Burrell, BA, MA, MBA**, EVERSANA, Flemington, NJ, USA

Panelists: **Chad Pettit, MBA, BSc**, Amgen, Thousand Oaks, CA, USA; **Ha Kung Wong, JD, MBA**, Venable Fitzpatrick, New York, NY, USA; **Joseph Franklin, PhD, JD**, US Food and Drug Administration, Silver Spring, MD, USA

## IP23: Can an Alternative Evaluation Approach, Addressing the Needs of the Purchaser Rather Than the Payer, Be the Answer to Standardizing the Information Set Used to Make Healthcare Purchasing Decisions? Rooms 393-394 (3rd Floor)

Moderator: **Laura T. Pizzi, PharmD, MPH, RPh**, Rutgers University, Piscataway, NJ, USA

Panelists: **Randy Vogenberg, PhD**, Institute for Integrated Healthcare, Employer Provider Interface Council of the Hospital Quality Foundation, Greenville, SC, USA; **Michael Bryan Pursel, BPharm, RPh, MBA, CHP**, Sanofi, Morrison, CO, USA; **Richard Bullard, BPharm**, Pharmacy Benefit Management Consultant, Phoenix, AZ, USA

## W16: Eliciting and Applying Patient Preference Information for Regulatory Decision-Making: What Have We Learned and Where Are We Going? Rooms 395-396 (3rd Floor)

Discussion Leaders: **Anindita Saha, BSE**, US Food & Drug Administration, Silver Spring, MD, USA; **Stephanie Christopher, MA**, Medical Device Innovation Consortium, Arlington, VA, USA; **Tonya Roney Moore**, WomenHeart: The National Coalition for Women with Heart Disease, Burlington, NC, USA; **Juan Marcos Gonzalez Sepulveda, PhD**, Duke University, Durham, NC, USA

# Wednesday May 22

## P15: Cost and Resource Use Studies Rooms 383-385 (3rd Floor)

- 8:30 - 8:45 **CR1 Patient Presentation, Complications and Health Resource Utilization Associated with Hardware Removal Within 1-Year After Open Reduction Internal Fixation of Femur Fractures**  
**Chitnis AS**<sup>1</sup>, Vanderkarr M<sup>2</sup>, Amoloja T<sup>1</sup>, Folly E<sup>3</sup>, Sparks C<sup>4</sup>, Holy CE<sup>1</sup>, <sup>1</sup>Johnson & Johnson, New Brunswick, NJ, USA, <sup>2</sup>DePuy Synthes, Inc., Raynham, MA, USA, <sup>3</sup>Johnson & Johnson, Raynham, MA, USA, <sup>4</sup>DePuy Synthes, West Chester, PA, USA
- 8:45 - 9:00 **CR2 US National Payers Analysis of the Incremental Healthcare Burden Among Patients with Treatment-Resistant Depression**  
Shrestha A<sup>1</sup>, Goutam P<sup>1</sup>, Roach M<sup>1</sup>, Everson K<sup>1</sup>, Sison S<sup>1</sup>, Joshi K<sup>2</sup>, **Sheehan JJ**<sup>2</sup>, Heerlein K<sup>2</sup>, Jena AB<sup>3</sup>, <sup>1</sup>Precision Health Economics, Los Angeles, CA, USA, <sup>2</sup>Janssen Pharmaceuticals, Titusville, NJ, USA, <sup>3</sup>Harvard Medical School, Boston, MA, USA
- 9:00 - 9:15 **CR3 Therapy Choice and Cost of Care in Patients with Advanced or Recurrent Endometrial Cancer Previously Treated with Platinum-Based Therapy: Analysis of US Claims Data**  
**Pothuri B**<sup>1</sup>, Perhanidis J<sup>2</sup>, Gibson CJ<sup>2</sup>, Brown J<sup>3</sup>, <sup>1</sup>New York University Langone Medical Center, NYU School of Medicine, New York, NY, USA, <sup>2</sup>TESARO, Inc., Waltham, MA, USA, <sup>3</sup>Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
- 9:15 - 9:30 **CR4 Resource Utilization within 30 Days of Car T Cells for Hematologic Malignancies**  
**Shah G**, Park J, Sauter C, Duck E, Halton E, Batlevi C, Palomba ML, Younes A, Geyer M, Smith E, Santomaso B, Perales MA, Sabatini P, Giralt S, Brenjens R, Bach PB, Memorial Sloan Kettering Cancer Center, New York, NY, USA

## P16: Treatment Patterns Rooms 386-387 (3rd Floor)

- 8:30 - 8:45 **TP1 Real-World Treatment Patterns Among Patients with Metastatic Urothelial Cancer Receiving Second-Line Therapy in the US Veteran Population**  
**Bhanegaonkar A**<sup>1</sup>, Kim R<sup>2</sup>, Pandya S<sup>3</sup>, Krulwicz S<sup>4</sup>, Wang L<sup>3</sup>, Pennock G<sup>1</sup>, Phatak H<sup>1</sup>, <sup>1</sup>EMD Serono, Inc., Rockland, MA, USA, <sup>2</sup>Pfizer, Inc., New York, NY, USA, <sup>3</sup>STATinMED Research, Plano, TX, USA, <sup>4</sup>Pfizer, Inc., Collegeville, PA, USA
- 8:45 - 9:00 **TP2 Community Rheumatologists' Experience and Views on Non-Medical Switching to Biosimilars**  
**Klink A**<sup>1</sup>, Yeh T<sup>2</sup>, Jeune-Smith Y<sup>2</sup>, Phillips Jr EG<sup>2</sup>, Feinberg BA<sup>2</sup>, <sup>1</sup>Cardinal Health Specialty Solutions, Philadelphia, PA, USA, <sup>2</sup>Cardinal Health Specialty Solutions, Dublin, OH, USA
- 9:00 - 9:15 **TP3 Factors Associated with Prescribing of Oral Disease Modifying Agents in Multiple Sclerosis**  
**Earla JR**<sup>1</sup>, Hutton GJ<sup>2</sup>, Thornton JD<sup>1</sup>, Aparasu RR<sup>1</sup>, <sup>1</sup>University of Houston, Houston, TX, USA, <sup>2</sup>Baylor College of Medicine Medical Center, McNair Campus, Houston, TX, USA
- 9:15 - 9:30 **TP4 Real-World Treatment Patterns for Patients with Metastatic Head and Neck Squamous Cell Carcinoma (MHNSSC) Treated with Immuno-Oncology (IO) Therapy**  
Huang H<sup>1</sup>, Shenolikar R<sup>2</sup>, Seal B<sup>2</sup>, **Tse J**<sup>1</sup>, Burudpakdee C<sup>3</sup>, <sup>1</sup>IQVIA, Cambridge, MA, USA, <sup>2</sup>AstraZeneca, Gaithersburg, MD, USA, <sup>3</sup>IQVIA, Fairfax, VA, USA

## P17: Conceptual Papers Rooms 391-392 (3rd Floor)

- 8:30 - 8:45 **CP1 It is All Relative! Impact of the Institute for Clinical and Economic Review (ICER) Budget Impact Threshold on Pricing Considerations**  
**Liu S**<sup>1</sup>, Migliaccio-Walle K<sup>2</sup>, Brown D<sup>1</sup>, <sup>1</sup>Xcenda, LLC, Palm Harbor, FL, USA, <sup>2</sup>Xcenda, Palm Harbor, FL, USA
- 8:45 - 9:00 **CP2 Estimating the Survival and Cost Impact of Introducing First-Line Alectinib and Osimertinib for Patients with Advanced NSCLC: An Iten Model Assessment**  
Moldaver D<sup>1</sup>, Zhou A<sup>1</sup>, **Grima D**<sup>1</sup>, Hurry M<sup>2</sup>, <sup>1</sup>Cornerstone Research Group, Burlington, ON, Canada, <sup>2</sup>AstraZeneca Canada, Mississauga, ON, Canada
- 9:00 - 9:15 **CP3 Eliciting Value Elements for a Patient-Driven Value Assessment**  
**Hong Y**, Zhang C, Slejko JF, dosReis S, University of Maryland School of Pharmacy, Baltimore, MD, USA
- 9:15 - 9:30 **CP4 Payer Perspectives on Patient Reported Outcomes Measures for Reimbursement Decision-Making in the United States**  
**Mesana L**<sup>1</sup>, Dubois de Gennes C<sup>2</sup>, Syed IA<sup>3</sup>, <sup>1</sup>Amaris, Jersey City, NJ, USA, <sup>2</sup>Amaris, Levallois-Perret, France, <sup>3</sup>Amaris, Toronto, ON, Canada

9:30AM - 2:00PM **POSTER & EXHIBIT HALL HOURS** Poster and Exhibit Hall, Hall H

# Wednesday May 22

9:30AM - 2:00PM **RESEARCH POSTER PRESENTATIONS – SESSION 5** Poster and Exhibit Hall, Hall H

9:45AM - 10:45AM **PhRMA FOUNDATION SESSION/AWARDS** Room 386-387 (3rd Floor)



This session will highlight the efforts of the four PhRMA Foundation Value Assessment Centers of Excellence and the new and diverse approaches they are using to capture and measure value. At the conclusion of this session, the Foundation will present their 2019 awards in Health Outcomes and Value Assessment to recognize the award recipients and promote these two areas of support of young scientists and research efforts.

*Moderator:* **Sachin Kamal-Bahl, PhD**, SKB Consulting Inc., Philadelphia, PA, USA

*Speakers:* **Susan dosReis, PhD**, University of Maryland School of Pharmacy, Baltimore, MD, USA; **George Miller, PhD**, Altarum, Ann Arbor, MI, USA; **Jonathan D. Campbell, PhD**, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA; **Peter J. Neumann, ScD**, Tufts Medical Center, Boston, MA, USA

9:45AM - 10:45AM **BREAKOUT SESSION 9**

**IP24: Can Meaningful Models Be Constructed for Rare Conditions?** Rooms 278-282 (2nd Floor)

*Moderator:* **C. Daniel Malone, PhD, RPh**, University of Arizona, Tucson, AZ, USA

*Panelists:* **Richard Chapman, PhD, MS**, Institute for Clinical and Economic Review, Boston, MA, USA; **Omar Dabbous, MD, MPH**, AveXis, Inc., Bannockburn, IL, USA; **Andrew Lloyd, DPhil**, Acaster Lloyd Consulting Limited, London, UK

**IP25: Is There an Urgent Need to Explore the Opportunities and Challenges of Wide Use of RWE in Medical Devices?** Rooms 391-392 (3rd Floor)

*Moderator:* **Lizheng Shi, PhD**, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA

*Panelists:* **Dongyi (Tony) Du, MD, PhD**, US Food and Drug Administration, Silver Spring, MD, USA; **Scott Tackett, MHA, MPH**, Surgical, Sunnyvale, CA, USA; **Somesh Nigam, PhD**, Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA

**IP26: Could Formal HTA Be the Solution to High Healthcare Costs in the USA?** Rooms 393-394 (3rd Floor)

*Moderator:* **Wrik Ghosh, BA, MSc**, Costello Medical Singapore Pte Ltd, Singapore, Singapore

*Panelists:* **Daniel A. Ollendorf, PhD**, Tufts Medical Center, Boston, MA, USA; **Thomas Butt, PhD**, Peking University, Beijing, China; **Sarah Breen, MA, MSc**, MSD UK, Hoddesdon, UK

**W18: Generating External Control Arms Using Real-World Data: Analytic Challenges and Recommendations**

Rooms 395-396 (3rd Floor)

*Discussion Leaders:* **Carrie Savage Bennette, PhD, MPH**, Flatiron, Seattle, WA, USA; **Blythe Adamson, PhD, MPH**, Flatiron Health, New York, NY, USA; **Anirban Basu, PhD**, University of Washington, Seattle, WA, USA

**W19: Health Economists Can Help Reduce the Uncertainty of the Risk in Value-Based Contracts!**

Rooms 388-390 (3rd Floor)

*Discussion Leaders:* **Anju Parthan, PhD**, Alkermes, Inc., Waltham, MA, USA; **Morgan Kruse, BA**, Optum, San Jose, CA, USA; **Kelly Fust, MS**, Optum, Plymouth, MA, USA; **Michele Kohli, PhD**, Quadrant Health Economics, Inc., Hamilton, ON, Canada

**P18: Diabetes Studies** Rooms 383-385 (3rd Floor)

9:45 - 10:00 **DM1 Disparities in the Quality of Care for Diabetes Among US Adults: The National Health and Nutrition Examination Survey (NHANES), 1999 to 2016**

**Kamat S<sup>1</sup>**, Muzumdar J<sup>2</sup>, Gousse Y<sup>3</sup>, Gu A<sup>3</sup>, <sup>1</sup>St. John's University, Queens, NY, USA, <sup>2</sup>College of Pharmacy and Health Sciences, St. John's University, Jamaica, NY, USA, <sup>3</sup>College of Pharmacy and Health Sciences, St. John's University, New York, NY, USA

10:00 - 10:15 **DM2 Adherence to DPP-4 Inhibitors vs Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis**

**Gor D<sup>1</sup>**, Lee TA<sup>2</sup>, Schumock G<sup>2</sup>, Walton SM<sup>3</sup>, Gerber B<sup>1</sup>, Nutescu EA<sup>4</sup>, Touchette D<sup>3</sup>, <sup>1</sup>University of Illinois at Chicago, Chicago, IL, USA, <sup>2</sup>University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA, <sup>3</sup>Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, <sup>4</sup>University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USA

10:15 - 10:30 **DM3 Quantifying the Opportunity to Reduce Total Cost of Care through Targeted Medication Prioritization and Adherence Improvement in Diabetes**

**Schneeweiss S<sup>1</sup>**, Eapen S<sup>2</sup>, Jan S<sup>3</sup>, <sup>1</sup>Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, <sup>2</sup>Aetion, Inc, Boston, MA, USA, <sup>3</sup>Horizon Blue Cross Blue Shield, Newark, NJ, USA

# Wednesday May 22

10:30 - 10:45 **DM4 Modeling the Incidence of Microvascular Complications at Glycemic Control Targets Recommended by the American Diabetes Association for Adult Patients with Type 1 Diabetes: An Analysis Using the Prime Diabetes Model** Pollock R<sup>1</sup>, Valentine WJ<sup>2</sup>, <sup>1</sup>Covalence Research Ltd, London, UK, <sup>2</sup>Ossian Health Economics and Communications GmbH, Basel, Switzerland

10:00AM - 11:00AM **ISPOR BOOTH EVENT** Poster and Exhibit Hall, Booth #407  
Take Control of Your ISPOR Experience: Update Your Member Profile and Email Preferences

11:00AM - 12:30PM **WELCOME & THIRD PLENARY SESSION** New Orleans Theater, Mid-Level Entrance

**Welcome From ISPOR President and ISPOR 2020 Conference Announcement**  
Federico Augustovski, MD, MSc, PhD, Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina

## THIRD PLENARY SESSION: IS AFFORDABILITY DRIVING A NEED TO REVOLUTIONIZE DRUG PRICING?

*Moderator:* Colleen M. Flood, University of Ottawa Centre for Health Law, Policy, and Ethics, Ottawa, ON, Canada  
*Speakers:* Muna Bhanji, RPh, Merck, Philadelphia, PA, USA; Meindert Boysen, PharmD, MSc, NICE, Manchester, England; John M. O'Brien, PharmD, MPH, US Department of Health and Human Services, Washington, DC, USA; Mark Trusheim, MS, NEWDIGS and MIT, Boston, MA, USA

12:30PM - 1:45PM **EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION 5** Poster and Exhibit Hall, Hall H

12:30PM - 2:00PM **LUNCH IN THE POSTER & EXHIBIT HALL** Poster and Exhibit Hall, Hall H

12:45PM - 1:45PM **POSTER AUTHOR DISCUSSION HOUR - SESSION 5** Poster and Exhibit Hall, Hall H

2:00PM - 3:00PM **BREAKOUT SESSION 10**

### W20: Improving Patient Access to Life-Saving Therapies: What Needs to Be Done to Fulfill the Promise of Biosimilars Rooms 391-392 (3rd Floor)

*Discussion Leaders:* Steven Simoens, MSc, PhD, KU Leuven, Leuven, Belgium; Cate Lockhart, PharmD, PhD, Biologics and Biosimilars Collective Intelligence Consortium, Greenbank, WA; Jacqueline Vanderpuye-Orgle, PhD, PAREXEL, Glendale, CA, USA; Delphine Courmier, PhD, MBA, AMGEN, Thousand Oaks, CA, USA

### W21: Identifying and Addressing Barriers to the Adoption of Standardized Outcome Measures in Patient Registries and Clinical Practice Rooms 393-394 (3rd Floor)

*Discussion Leaders:* Richard Gliklich, MD, OM1, Boston, MA, USA; Elise Berliner, PhD, Agency for Healthcare Research and Quality, Rockville, MD, USA

### W22: Beyond Trial Replication: Using Real-World Data to Bridge the Efficacy-Effectiveness Gap in Healthcare Rooms 395-396 (3rd Floor)

*Discussion Leaders:* David Thompson, PhD, Syneos Health, Manchester, MA, USA; Manfred Stapff, MD, PhD, TriNetX Inc., Cambridge, MA, USA; Joseph Dicesare, MPH, Allergan, Madison, NJ, USA

### W23: Getting the Most Out of Value-Based Contracting for Medical Devices Rooms 388-390 (3rd Floor)


*Discussion Leaders:* Jyoti Aggarwal, MHS, Pharmerit International, Bethesda, MD, USA; Vasudha Bal, MSc, MBA, BD, Franklin Lakes, NJ, USA; Trevor Wear, JD, MHA, Sidley Austin LLP, Chicago, IL, USA; Dale Cooke, MA, JD, PhillyCooke Consulting, Penn Valley, PA, USA

### W24: Patient-Focused Drug Development: Operational Considerations for Conducting Qualitative Research in Special Populations Rooms 383-395 (3rd Floor)

*Discussion Leaders:* Elizabeth (Nicki) Bush, MHS, Eli Lilly and Company, Indianapolis, IN, USA; Selena Daniels, PharmD, MS, US Food and Drug Administration, Silver Spring, MD, USA; Shannon Keith, MS, Clinical Outcomes Solutions, Chicago, IL, USA; Kim Kelly, PhD, Clinical Outcomes Solutions, Tucson, AZ, USA



# Good Practices for Outcomes Research



- Setting international standards with consensus guidance recommendations
- Recognized with a “Power of A” Award that acknowledges innovative, effective, and broad-reaching programs that positively impact the world



©2019 ISPOR – The professional society for health economics and outcomes research

## Tell Us What You Think

### ISPOR Conference Evaluation

#### **We're listening.**

Please complete a simple online evaluation after the conference to help us plan for future conferences. It's simple—answer a few multiple-choice questions by Friday, June 7, 2019, using the ISPOR conference app or on the ISPOR website at [www.ispor.org](http://www.ispor.org).

*Be a voice and help us plan for 2019.*

### ISPOR Session Evaluation

#### **Have thoughts about a particular session? We're interested.**

- Evaluate presentations through the ISPOR conference app
- Provide real-time responses immediately following the presentation
- 2-question evaluation for each presentation that can be accessed through the description portion of the presentation on the app.

# Invitational Group Meetings

Many ISPOR Member Groups meet in person during the conference to work on projects, reports, articles and other specific tasks that advance their group's objectives. These member groups include: Special Interest Groups (SIGs), Task Forces (TF), Councils & Roundtables, Consortium, Networks, and Chapters. **Invitational Group Meetings are by invitation only.**

Participants will receive an email reminder and notification of any changes to the group meeting schedule from the ISPOR Staff or ISPOR member coordinating the meeting. Invitational Group Meetings are included in the conference app daily schedule to allow invited participants the option to add the meeting to their personal schedule.

Visit [www.ispor.org](http://www.ispor.org) >>Member Groups for information on how to join the many member groups.

<b>Sunday, May 19</b> 12:00PM - 1:00PM LUNCH ON YOUR OWN FOR SHORT COURSE DELEGATES		
8:30AM - 5:30PM	ISPOR Health Technology Assessment - Pharmacy & Therapeutics (HTA-P&T) Roundtable - North America	Room 291 (2nd Floor)
12:00PM - 1:00PM	ISPOR Joint Councils Luncheon	Room 289 (2nd Floor)
1:00PM - 4:00PM	ISPOR Institutional Council Roundtable	Room 288 (2nd Floor)
1:00PM - 4:00PM	ISPOR Student Network Leadership Retreat	Room 397 (3rd Floor)
2:30PM - 3:30PM	ISPOR Publications Management Advisory Board (MAB)/ISPOR Journal Editors-in-Chief Joint Business Meeting	Room 398 (3rd Floor)
<b>Monday, May 20</b> 12:00PM - 1:30PM LUNCH FOR DELEGATES SERVED IN THE POSTER EXHIBIT HALL		
7:00AM - 8:15AM	ISPOR Machine Learning Task Force Proposal Group	Room 399 (3rd Floor)
7:15AM - 8:15AM	ISPOR Statistical Methods Special Interest Group	Room 297 (2nd Floor)
7:15AM - 8:15AM	ISPOR <i>Value &amp; Outcomes Spotlight</i> Editorial Advisory Board	Room 288 (2nd Floor)
7:15AM - 8:15AM	ISPOR Health Preference Methods Special Interest Group	Room 398 (3rd Floor)
7:15AM - 8:15AM	ISPOR Oncology Special Interest Group	Room 289 (2nd Floor)
7:15AM - 8:15AM	ISPOR Biosimilar Special Interest Group	Room 290 (2nd Floor)
11:00AM - 12:30PM	ISPOR Patient Preference Measurement Task Force Proposal Group	Room 398 (3rd Floor)
11:00AM - 12:15PM	ISPOR Medical Devices and Diagnostics Special Interest Group	Room 297 (2nd Floor)
12:00PM - 1:00PM	ISPOR CEE Consortium	Room 289 (2nd Floor)
12:15PM - 4:45PM	ISPOR Patient Representatives Roundtable - North America	Room 291 (2nd Floor)
1:00PM - 2:00PM	ISPOR Midwest Chapter	Room 288 (2nd Floor)
1:00PM - 2:00PM	ISPOR Africa Network	Room 289 (2nd Floor)
1:00PM - 2:00PM	ISPOR Asia Consortium Industry Committee	Room 290 (2nd Floor)
4:00PM - 5:00PM	ISPOR Past Presidents Council	Room 288 (2nd Floor)
5:00PM - 7:00PM	ISPOR International Initiatives on the Assessment of the Value of Medical Technologies Working Group	Room 398 (3rd Floor)
5:15PM - 7:15PM	ISPOR Chapter Leadership Training	Room 397 (3rd Floor)
7:30PM - 9:00PM	ISPOR <i>Value in Health</i> Editorial Board and Editorial Advisory Board	Room 290 (2nd Floor)

# Invitational Group Meetings

**Tuesday, May 21** 12:00PM-1:30PM LUNCH FOR DELEGATES SERVED IN THE POSTER EXHIBIT HALL

7:15AM - 8:15AM	ISPOR Open Source Models Special Interest Group	Room 399 (3rd Floor)
7:15AM - 8:15AM	ISPOR Patient Centered Special Interest Group	Room 398 (3rd Floor)
7:15AM - 8:15AM	ISPOR Clinical Outcomes Assessment Special Interest Group	Room 297 (2nd Floor)
11:00AM - 12:00PM	ISPOR Open Source Models Task Force	Room 399 (3rd Floor)
12:00PM - 1:00PM	ISPOR Colombia Chapter	Room 398 (3rd Floor)
12:00PM - 1:00PM	ISPOR Arabic Network	Room 289 (2nd Floor)
12:00PM - 2:00PM	ISPOR Student and Faculty Luncheon	Room 397 (3rd Floor)
2:00PM - 3:30PM	ISPOR Education Council	Room 290 (2nd Floor)
3:30PM - 4:30PM	ISPOR Student Roundtable	Room 397 (3rd Floor)
3:45PM - 4:45PM	ISPOR <i>Value in Health Regional Issues</i> Editorial Board & Editorial Advisory Board	Room 398 (3rd Floor)
3:45PM - 5:15PM	ISPOR Performance Based Outcomes (PerfO) Task Force	Room 399 (3rd Floor)
7:00PM - 8:30PM	ISPOR Health Technology Assessment (HTA) Council	Room 290 (2nd Floor)

**Wednesday, May 22** 12:30PM - 2:00PM LUNCH FOR DELEGATES SERVED IN THE POSTER EXHIBIT HALL

7:15AM - 8:15AM	ISPOR Personalized/Precision Medicine Special Interest Group	Room 399 (3rd Floor)
7:15AM - 8:15AM	ISPOR Real-World Evidence Special Interest Group	Room 288 (2nd Floor)
7:15AM - 8:15AM	ISPOR Digital Health Special Interest Group	Room 398 (3rd Floor)
9:00AM - 10:00AM	ISPOR Boston Chapter	Room 397 (3rd Floor)

# ISPOR Publications

## Get published. Get noticed.



ISPOR's family of publications provide ample opportunities to contribute to the science and understanding of health economics and outcomes research (HEOR). Whether you're conducting research for publication in peer-reviewed journals or writing about the everyday use and application of HEOR in healthcare decisions, submitting your research to ISPOR's publications is an excellent way to get noticed and advance the field.



**Value in Health** is an international, indexed journal that publishes original research and health policy articles that help healthcare leaders make evidence-based decisions.

**Value in Health Regional Issues** is an online, MEDLINE®-indexed journal that focuses on health-related topics that impact the health systems in the following regions: 1) Asia; 2) Central and Eastern Europe, Western Asia, and Africa; and 3) Latin America.

**Value & Outcomes Spotlight** is a bimonthly HEOR news magazine that covers timely HEOR topics, updates from ISPOR leadership, and HEOR news from around the world.

505 Lawrence Square Blvd South, Lawrenceville, NJ 08648

© ISPOR – The professional society for health economics and outcomes research

[www.ispor.org](http://www.ispor.org)

## Benefits of Membership

**Become a member of the global HEOR community:**

- World-class, global scientific conferences
- MEDLINE®-indexed publications
- Knowledge products and online tools
- Educational and training programs
- Awards and recognition
- Career development

[www.ispor.org/membership](http://www.ispor.org/membership)



# ISPOR 2019



## Poster & Exhibit Program

### Research Poster Presentations Overview

### Exhibit Program Overview

### Exhibitor Listing

### Poster & Exhibit Hall Floor Plan

## NEW! ISPOR 2019 Exhibitor HEOR Theater\*

### *Continue your education at the ISPOR 2019 Exhibitor HEOR Theater!*

Be sure to make time in your conference schedule to attend these 30-minute insightful, informative, and educational sessions presented by ISPOR 2019 Exhibiting Companies. Exhibitor HEOR Theater is located in the Exhibit Hall.

#### MONDAY, MAY 20

11:15AM - 11:45AM

##### **Getting to the "Why": Gaining Additional Insights for HEOR Studies Through Diagnostic Laboratory Data**

*Presenters:* Heather von Allmen, General Manager, Explorer Product, Prognos; Mohdhar Habib, Director, Global Health Economics, Amgen



2:30PM - 3:00PM

##### **Demonstrating the Use of Constrained Optimization on A Real-World Problem**

*Presenters:* Katherine A. Hicks, MS, Director of Health Economics, RTI Health Solutions (RTI-HS), Durham, NC, USA; Stephanie R. Earnshaw, PhD, Vice President of Health Economics, RTI Health Solutions (RTI-HS), Durham, NC, USA



4:00PM - 4:30PM

##### **Critical Pitfalls to Avoid in Value-Based Contracting and Engaging in Value-Based Efforts**

*Presenter:* Steve Carter, Senior Vice President, Global Pricing and Product Strategy, Precision Xtract



#### TUESDAY, MAY 21

11:15AM - 11:45AM

##### **Integrated Research – A New Operating Model to Enable Research and Real-World Data as a Natural Output of Clinical Practice**

*Presenters:* Stephanie Reisinger, Vice President, General Manager Veradigm Life Sciences



2:30PM - 3:00PM

##### **Linked Data Breakthrough Delivers Major Advancement for PRO and Clinical Research**

*Presenters:* Lulu K. Lee, PhD, Vice President, Health Outcomes Research, Kantar; Tom Haskell, Global Head of Data Analytics, Kantar



4:00PM - 4:30PM

##### **Making the Patient Voice Count – Demonstrating When, Why, and How to Engage Patients**

*Presenters:* Caitlyn Solem, PhD, Executive Director, Patient-Centered Outcomes Pharmerit International; Kelly McCarrier, PhD, MPH, Director and Qualitative Research Lead, Patient-Centered Outcomes Pharmerit International



\*The HEOR Theater presentations are not an official educational offering of ISPOR 2019, and are not sponsored, endorsed or accredited by ISPOR.



# Research Poster Presentations Overview

**More than 1700 poster presentations will be on display during the conference in the Poster & Exhibit Hall H (1st fl).**

- The poster hall is organized in rows (A-N) and each poster board is numbered accordingly (eg, A1, L15). Each poster has been assigned a specific numbered board location.
- Poster presentations also are available on the myISPOR2019.zerista.com web platform and mobile app.
- Presenting authors will be with their posters during the Poster Author Discussion Hour.
- An author index will be available in *Value in Health* (Volume 22, Suppl 1). The issue will be ONLINE ONLY, available 1 month after the meeting.

## Poster Presentations Display Hours

POSTER PRESENTATION SESSIONS	POSTER LOCATION	PRESENTER SET-UP TIME	POSTER DISPLAY HOURS	AUTHOR DISCUSSION HOUR	PRESENTER DISMANTLE TIME*
<b>SESSION 1: MONDAY, MAY 20</b>					
PCN: CANCER	Rows: A-K	8:00AM – 10:30AM	10:30AM – 2:00PM	1:00PM – 2:00PM	2:00PM
PGI: GASTROINTESTINAL DISORDERS	Rows: K				
PIT: INJURY & TRAUMA	Rows: L				
PVM: VETERINARY MEDICINE	Rows: L				
<b>SESSION 2: MONDAY, MAY 20</b>					
PDB: DIABETES/ENDOCRINE/METABOLIC DISORDERS	Rows: A-E	3:00PM – 3:30PM	3:30PM – 7:00PM	6:00PM – 7:00PM	7:00PM
PIH: INDIVIDUAL'S HEALTH	Rows: E-G				
PMH: MENTAL HEALTH	Rows: G-I				
PMS: MUSCULOSKELETAL DISORDERS	Rows: I-K				
PSU: SURGERY	Rows: K-L				
<b>SESSION 3: TUESDAY, MAY 21</b>					
PAM: ALTERNATIVE MEDICINE & NUTRITION	Rows: A	8:00AM – 10:30AM	10:30AM – 2:00PM	1:00PM – 2:00PM	2:00PM
PBI: BIOLOGICS/BIOSIMILARS/REGENERATIVE MEDICINE	Rows: A-B				
PCV: CARDIOVASCULAR DISORDERS	Rows: B-F				
PIN: INFECTIOUS DISEASES	Rows: F-I				
PND: NEUROLOGICAL DISORDERS	Rows: I-L				
<b>SESSION 4: TUESDAY, MAY 21</b>					
PDG: DRUGS & GENERICS	Rows: A-D	3:00PM – 3:30PM	3:30PM – 7:00PM	6:00PM – 7:00PM	7:00PM
PMU: MULTIPLE DISEASES	Rows: D-G				
PRO: RARE & ORPHAN DISEASES	Rows: G-I				
PRS: RESPIRATORY-RELATED DISORDERS	Rows: I-L				
PUK: URINARY/KIDNEY DISORDERS	Rows: L				
<b>SESSION 5: WEDNESDAY, MAY 22</b>					
PMD: MEDICAL DEVICES	Rows: A-B	8:00AM – 9:30AM	9:30AM – 2:00PM	12:45PM – 1:45PM	2:00PM
PNS: NO SPECIFIC DISEASE	Rows: B-J				
PPM: PERSONALIZED & PRECISION MEDICINE	Rows: J-K				
PSS: SENSORY SYSTEM DISORDERS	Rows: K				
PSY: SYSTEMIC DISORDERS/CONDITIONS	Rows: K-L				

\*Posters that are not removed at the scheduled dismantle times will be discarded.

# Exhibit Program Overview

## Exhibit Viewing Hours (Hall H)

Monday, May 20	10:30AM - 7:30PM (Welcome Reception 6:00PM - 7:30PM)
Tuesday, May 21	10:30AM - 7:30PM (Networking Reception 6:00PM - 7:30PM)
Wednesday, May 22	9:30AM - 2:00PM

## Exhibitor HEOR Theater Hours (Hall H)

### Monday, May 20

11:15AM - 11:45AM	Prognos
2:30PM - 3:00PM	RTI
4:00PM - 4:30PM	Precision Health Economics - Precision Xtract

prognos

RTI Health Solutions



### Tuesday, May 21

11:15AM - 11:45AM	Veradigm Health
2:30PM - 3:00PM	Kantar
4:00PM - 4:30PM	Pharmerit



KANTAR



## Networking and Lounges

Charging Lounge	Provided by EVERSANA, Johnson & Johnson, Veradigm Health, Poster & Exhibit Hall
Wi-Fi	Network: ISPOR2019 Password: HEALTHCORE Sponsored by HealthCore



## Sunday, May 19

8:00AM - 11:59PM	Exhibitor Set-Up (No re-entry after 10:00PM)
------------------	--

## Monday, May 20

7:00AM - 10:30AM	Exhibitor Set-Up
10:30AM - 7:30PM	Exhibits Viewing
10:30AM - 11:00AM	Coffee Break & Exhibits Viewing
12:00PM - 1:30PM	Lunch
12:00PM - 2:00PM	Exhibits & Research Poster Presentations Viewing
3:15PM - 3:45PM	Coffee Break & Exhibits Viewing
6:00PM - 7:30PM	Welcome Reception Sponsored by Evidera



## Tuesday, May 21

10:30AM - 7:30PM	Exhibits Viewing
10:30AM - 11:00AM	Coffee Break & Exhibits Viewing
12:00PM - 1:30PM	Lunch
12:00PM - 2:00PM	Exhibits & Research Poster Presentations Viewing
3:15PM - 3:45PM	Coffee Break & Exhibits Viewing
6:00PM - 7:30PM	Networking Reception Provided by ISPOR



## Wednesday, May 22

9:30AM - 2:00PM	Exhibits Viewing
9:30AM - 10:00AM	Coffee Break & Exhibits Viewing
12:30PM - 2:00PM	Exhibits & Research Poster Presentations Viewing
12:30PM - 2:00PM	Lunch
2:00PM - 10:00PM	Exhibitor Dismantle


# Exhibitor Listing

Company Name	Booth Number	Company Name	Booth Number	Company Name	Booth Number
Adelphi Real World & Adelphi Values	201	FACT.org/FACITtrans	303	Real Life Data SLU	403
Aetion	803	FIECON	603	<b>RTI Health Solutions*</b>	<b>507</b>
Amaris Consulting UK Ltd	902	Future Science Group	211	Rutgers University	Table 4
AMPLEXOR	1004	Genesis Research	1011	RWS Life Sciences	909
Analysis Group	405	<b>HealthCore, Inc*</b>	<b>401</b>	Scientist.com	302
AplusA	1007	Huron	706	Self Care Catalysts	404
AstraZeneca	1012	<b>IBM Watson Health</b>	<b>911</b>	SHYFT Analytics	813
Barrington James	1009	<b>ICON</b>	<b>1001</b>	SIRIUS Market Access	1017
Black Swan Analysis Ltd	413	Ipsos HealthCare	409	snapIoT	307
BHE	203	<b>IQVIA</b>	<b>505</b>	STATinMED Research	1000
Boston Strategic Partners, Inc	308	<b>ISPOR</b>	<b>407</b>	Syneos Health	901
Bristol-Myers Squibb	702	JMDC Inc	415	Taylor & Francis	506
Cardinal Health	809	Journal of Health Economics and Outcomes Research	Table 7	The American Journal of Managed Care	819
CERobs Consulting, LLC	Table 5	<b>Kantar*</b>	<b>900</b>	TransPerfect	806
<b>Certara Evidence &amp; Access*</b>	<b>300</b>	KMK Consulting, Inc	406	TreeAge Software	916
Clinakos Inc	514	Lighthouse Outcomes	703	<b>TriNetX*</b>	<b>601</b>
Clinical Practice Research Datalink (CPRD)	914	Mapi Research Trust	1005	Tufts Medical Center	918
<b>CHEORS</b>	<b>509</b>	Market Access Transformation	605	Universite de Bordeaux	802
Cornerstone Research Group Inc	907	Mckesson	502	University of Maryland – Pharmaceutical Health Services Research Graduate Program	Table 1
Costello Medical	310	Monument Analytics	205	Veradigm*	805
Creativ-Ceutical	410	Normin Health Consulting	Table 8	Verantos, Inc	Table 3
CTI Clinical Trial & Consulting Services	903	Northwestern University	Table 9	Vitaccess Limited	1008
Currant	Table 6	Novosys Health	215	Worldwide Clinical Trials	707
Datacubed Health	908	OM1	306	Xavier University	Table 2
Decision Resources Group	1002	<b>OPEN VIE</b>	<b>512</b>	<b>Xcenda</b>	<b>501</b>
Digital Health Outcomes	821	<b>Optum</b>	<b>815</b>	YPrime	312
Dymaxium, Inc	609	PAREXEL	905	ZS	607
eMAX Health Systems, LLC	402	Pharmerit International*	801		
EPI-Q, Inc	213	Policy Analysis, Inc	209		
Evalueserve	705	PRA Health Sciences	807		
Evidence Partners	411	<b>Precision Xtract/Precision Health Economics*</b>	<b>611</b>		
<b>Evidera*</b>	<b>503</b>	Premier	817		
Exponent	811	PRMA Consulting	207		
		Prognos*	Table 10		

*\*Sponsoring Organizations*

# Poster & Exhibit Hall Floor Plan

## Hall H



Interested in exhibiting or sponsoring at a future ISPOR conference?

Contact [sponsor@ispor.org](mailto:sponsor@ispor.org)

## ISPOR Science and Service Awards Program

The ISPOR Science and Service Awards Program is designed to foster and recognize excellence and outstanding technical achievement in health economics and outcomes research (HEOR). ISPOR also awards lifetime achievement and leadership awards to those who advance these disciplines in the field and by service to the Society.



### *Featured Award Recipients*

#### **2019 ISPOR AVEDIS DONABEDIAN OUTCOMES RESEARCH LIFETIME ACHIEVEMENT AWARDEE**

Marc L. Berger, MD, Consultant, New York, NY, USA

#### **2019 ISPOR MARILYN DIX SMITH LEADERSHIP AWARDEE**

Josephine Mauskopf, PhD, RTI Health Solutions, Research Triangle Park, NC, USA



### *Additional 2019 ISPOR Scientific Achievement Awards*

#### **Bernie J. O'Brien New Investigator Award**

Zirui Song, MD, PhD, Harvard Medical School, Boston, MA, USA

#### **Value in Health Paper of The Year Award**

Mónica Hernández, MSc, PhD, University of Sheffield, Sheffield, UK

#### **Value in Health Regional Issues Excellent Article Awards**

José Miguel Uribe-Restrepo, MD, MPH, Javeriana University Medical School, Bogotá, Colombia

Alexandra Beletsi, PharmD, PhD, Servier Hellas Pharmaceuticals EPE, Athens, Greece

#### **Award for Excellence in Methodology in Health Economics and Outcomes Research**

A. James O'Malley, MS, PhD, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA

#### **Award for Excellence in Application of Health Economics and Outcomes Research**

William V. Padula, PhD, MS, University of Southern California, Los Angeles, CA, USA

*Awardees are being honored at the ISPOR Inaugural Awards Banquet on Sunday, May 19, 2019.*



### 2019 ISPOR AVEDIS DONABEDIAN OUTCOMES RESEARCH LIFETIME ACHIEVEMENT AWARD

ISPOR's most prestigious award, the Avedis Donabedian Outcomes Research Lifetime Achievement Award, was established to honor the body of work and contributions to the field made by the late Avedis Donabedian, MD, MPH. The Award recognizes an individual's outstanding, life-long achievement in improving health outcomes.

### 2019 ISPOR AVEDIS DONABEDIAN OUTCOMES RESEARCH LIFETIME ACHIEVEMENT AWARDEE

**Marc L. Berger, MD**, Consultant, New York, NY, USA



Marc L. Berger, MD, is a semi-retired, part-time consultant. Until July 2017, he was vice president, Real World Data and Analytics at Pfizer, Inc. Marc has held senior-level positions in industry including executive vice president and senior scientist at OptumInsight; vice president, Global Health Outcomes at Eli Lilly and Company; and vice president, Outcomes Research and Management at Merck & Co., Inc. He currently serves as advisor to several companies, including SHYFT Analytics.

Additionally, Marc contributes to ongoing efforts by ISPOR and the Duke-Margolis Center for Health Policy to recommend how real-world evidence can be produced to enhance and expand its usefulness for regulatory agencies and other healthcare authorities. Marc has written or cowritten more than 130 peer-reviewed articles, book chapters, and other publications on a range of topics, including health services research, outcomes research, health economics, and health policy.



### 2019 ISPOR MARILYN DIX SMITH LEADERSHIP AWARD

The Marilyn Dix Smith Leadership Award was established in 2014 in honor of ISPOR's Founding Executive Director, Marilyn Dix Smith, RPh, PhD. The Award recognizes one individual each year that has provided extraordinary leadership to the Society.

### 2019 ISPOR MARILYN DIX SMITH LEADERSHIP AWARDEE

**Josephine Mauskopf, PhD**, RTI Health Solutions, Research Triangle Park, NC, USA



Josephine Mauskopf, PhD, is vice president of Health Economics at RTI Health Solutions. She has over 30 years of experience both as a consultant and within the pharmaceutical industry designing and implementing health economic research strategies for prevention and treatment of infectious diseases, psychiatric illness, and neurologic diseases. She has been an active member of ISPOR since its beginning. She has presented posters, podiums, workshops, and issues panels regularly at the international and European conferences. She served as editor-in-chief for *Value in Health* from 2002 to 2010. She cochaired 3 ISPOR task forces: 2 for budget impact analysis and 1 for economic evaluation of vaccination programs and served on the CHEERS Task Force. The Budget Impact Analysis Task Force Report and related publications have served as the basis for country-specific guidelines. With other ISPOR members, she developed and presented a premeeting course on budget impact analysis that has trained many ISPOR attendees. She served on the ISPOR Board of Directors from 2014 to 2016.



Optimizing patient  
access with evidence  
of product **value,**  
**effectiveness & safety**

**Real-World Evidence**

**Patient-Centered Research**

**Evidence Synthesis,  
Modeling & Communication**

**Market Access**

**Interventional Studies**

**Pragmatic Studies**

**Medical Writing**

**JOIN OUR TEAM. MAKE YOUR WORK MATTER.**

We are growing rapidly and looking to expand our team with people who want to make a difference, grow their careers, and work in a collaborative environment with some of the best in the industry.

We are actively  
recruiting for positions  
in all areas.

► Visit [evidera.com/careers](https://evidera.com/careers) to view all open positions.

**evidera.com**

# CHEORS

COMPLETE HEOR SOLUTIONS

For All Your HEOR Needs Round-the-Clock!

Economic Modeling | Real World Large Data Studies | Dossier | Medical Writing

**Over 150 HTA Submissions Completed**  
**across 40 countries Worldwide**  
**in just 4 years!**



## Why Choose CHEORS?

- Senior team each with 15-25 years of in-house pharmaceutical industry experience
- Highly technical staff leads every project
- Flexibility to put larger teams to deliver on tight timelines

**Our unique database analysis solution allowed one client to complete more than 25 studies in less than a year**

## Contact us to Learn More!

**We have offices in Canada, U.S., and Asia and we can be reached at:**

Michael Marentette: [michael.marentette@cheors.com](mailto:michael.marentette@cheors.com)

Bridget Corbett: [bridget.corbett@cheors.com](mailto:bridget.corbett@cheors.com)

**We are hiring, please visit our booth!**



HOW CAN WE SOLVE HEALTH CARE  
PROBLEMS BEFORE THEY EVEN ARISE?



WE KNOW HOW. WE ARE THE HOW.

Visit us at booth 815 during ISPOR 2019 in New Orleans.

[OPTUM.COM](http://OPTUM.COM)





Reframe the  
debate on the  
value of your  
healthcare  
innovation



Precision is in New Orleans and ready to troubleshoot your challenges—schedule a complimentary 15-minute consultation with some of the most well-regarded experts in the field today.

**To schedule your 15-minute time slot with an expert, stop by Booth 611 during ISPOR or email us at: [info@precisionhealtheconomics.com](mailto:info@precisionhealtheconomics.com)**

#### Three of the Precision experts in attendance:



**Anupam Jena, MD, PhD**  
Scientific Advisor,  
Associate Professor of Health Policy,  
Harvard Medical School



**Jeroen Jansen, PhD**  
Chief Scientist



**Ross Maclean, MD, PhD, MBA**  
Executive Vice President,  
General Manager







Global reach.

Local expertise.

When your market access needs take you anywhere and everywhere . . . partner with Xcenda.

Visit us at Booth #501. Connect with us anytime at [www.xcenda.com](http://www.xcenda.com).



## EVIDENCE & ACCESS



Market Access  
& Value Strategy



Decision Analytics  
& Modelling



BaseCase Stakeholder  
Communication Platform



Real World  
Evidence Solutions



Innovative & Outcomes  
Based Contracting



Value Frameworks  
& MCDA

*Learn more about our expertise at booth #300*



Our integrated research environment is more robust now than ever before. We've added new and growing streams of **integrated clinical data** and large volumes of **directly accessible, integrated clinical oncology data** for deeper insights for your entire product life cycle – from clinical development through real-world evidence. We take pride in providing you a holistic view and delivering scientific expertise, user experience, and clinical outcomes to support you wherever you are in your journey.

Visit **booth 401** at ISPOR in New Orleans.





# Big data. Bigger analytics.

Combine world-class big data, analytics and AI to increase efficiency in your research and accelerate time to value.

Visit us at Booth #911

© Copyright IBM Corporation 2019. IBM, the IBM logo and ibm.com are trademarks of IBM Corporation in the United States, other countries or both. Other product and service names might be trademarks of IBM or other companies.




## Together we improve outcomes.

ICON's Commercialisation & Outcomes experts deliver integrated solutions to identify, generate, synthesise and communicate the outcomes evidence that regulators, payers, providers and patients need to make informed health decisions.

**ICON and You.**  
**Partners making a difference.**

[ICONplc.com/commercialisation](https://iconplc.com/commercialisation)





When evidence speaks  
the world listens.

>>> > > > >>>

>> >>>> > > > > >>>>>>

Real world data and advanced technologies are shortening timelines, improving the impact of research investments, and helping therapies reach patients faster. Use external comparators to accelerate clinical development. Use evidence platforms for on-demand analytics. The possibilities are exciting.

*Others may offer a way forward. IQVIA gives you a way further.*


YOUR  
WAY  
FURTHER

IMS Health & Quintiles are now  
**IQVIA**<sup>TM</sup>

>> >>>> > > > > >>>>>>

>> >>>> > > > > >>>>>>

[IQVIA.COM/FURTHER](https://www.iqvia.com/further)



**CLARITIS<sup>TM</sup>**


**THE LINK BETWEEN DATA  
AND EVIDENCE.**

For the first time ever, companies are able to uncover previously unseen insights about the patient by linking of Patient Reported Outcomes and Clinical Data together using Kantar's Claritis solution.

Visit us at Booth #900 to learn more from our experts about this new linked data solution.

[www.kantarhealth.com](https://www.kantarhealth.com)

**KANTAR**



## Better Health, Brighter Future

At Takeda Oncology, we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.

We know that our mission is not a quick or simple one, but we are up for the task: **we aspire to cure cancer.**



ONCOLOGY

To learn more, visit us at [takedaoncology.com](http://takedaoncology.com).

 @TakedaOncology

©2019 Millennium Pharmaceuticals, Inc. All rights reserved.



# ISPOR

*Improving healthcare decisions*

*Thank you to our supporting  
companies and institutions.*

## HEOR RESOURCES Comprehensive Tools. Comprehensive Knowledge.

ISPOR members, through its working groups, have developed a rich repository of HEOR resources that set the standard for research excellence in the field. Interest in the field of health economics and outcomes research (HEOR) has grown exponentially as governments and other payers grapple with how to provide the best possible health outcomes at affordable costs. At ISPOR, we believe that every healthcare decision should be informed by the best scientific research derived from rigorous, proven methodologies. Toward that goal, the Society's mission is to promote HEOR excellence to improve decision making for health globally.

*Good Practices for Outcomes Research*  
*Pharmacoeconomic Guidelines Around the World*  
*Global Healthcare Systems Road Maps*  
*Scientific Presentations Database*  
*International Digest of Databases*  
*Assessing the Evidence for Decision Makers*  
*Outcomes Research Guidelines Index*  
*Health Technology Assessment Central*

[www.ispor.org](http://www.ispor.org)



# ISPOR

*Improving healthcare decisions*



- 1 DRUG SPENDING AND PRICING**  
This subject has expanded beyond the pricing of pharmaceuticals to encompass drug spending and its impact on payers' healthcare budgets.  

- 2 GOING BEYOND UNIVERSAL HEALTH COVERAGE**  
Universal healthcare cannot be universal without ensuring that patients do not face undue barriers to accessing healthcare.  

- 3 REAL-WORLD EVIDENCE**  
There is increasing interest and potential for converting real-world data into real-world evidence to inform healthcare decision making.  

- 4 AGING POPULATION**  
Elder care and long-term care will continue to be global healthcare challenges as the number of people in the world aged 60 years or older continues to grow.  

- 5 PRICE TRANSPARENCY: NOT JUST ABOUT DRUGS**  
The lack of transparency in the pricing of healthcare services impedes consumers' healthcare decision making.  

- 6 "BIG DATA" CONTINUE TO MAKE NOISE**  
The use of "big data" can assist clinicians in making better healthcare decisions for their patients.  

- 7 VALUE ASSESSMENT FRAMEWORKS**  
Value assessment frameworks can be an important element in moving towards a more value-based care model.  

- 8 HEALTHCARE DECISION MAKING IN LOW-INCOME COUNTRIES**  
The difference between health technology assessment use by high-income and low-income countries is notable.  

- 9 PERSONALIZED/PRECISION MEDICINE**  
As researchers continue to determine the roles that genes play in diseases, HEOR will be needed to evaluate the diagnostics and drugs derived from their discoveries.  

- 10 UNHEALTHY BEHAVIORS**  
The root causes of many chronic diseases include a host of unhealthy behaviors that lead to a variety of diseases responsible for the majority of all deaths worldwide.  


## Key Information

### WI-FI, INTERNET AND CONFERENCE APP ACCESS

**Network:** ISPOR2019 **Password:** HEALTHCORE

Wi-Fi is available in the convention center. Wi-Fi is only intended for checking email and using the conference mobile app, not for downloading files. Connection speeds will vary depending on the volume of users. Download the mobile app on your smartphone or tablet:



Can't download the app? Use your web browser: <https://myISPOR2019.zerista.com/>  
Use the same details as used for the myISPOR2019 web pages. Your ISPOR conference app account email address is the same email address used for your conference registration. Need help? Select "Need help logging in?" on the login screen.

Wi-Fi Sponsored by HealthCore, Inc.



### REGISTRATION DISCLAIMER

For security purposes all individuals must be registered and wear the official ISPOR Conference Name Badge to gain access to the conference, the sessions, the exhibit poster hall, and any other ISPOR activity. Onsite staff and security will monitor for name badges and will deny access if an individual does not have an official ISPOR Conference Name Badge. Individuals not wearing a name badge will be directed to registration. Please note that if you lose your name badge and need to have it reprinted you cannot print that at the self-serve station; you will need to visit the registration help desk.

Because of the professional nature of the program, and safety and liability reasons, guests and anyone under the age of 18 are not permitted access to or to register for the conference. This includes access to the conference in general, to scientific presentations, and to the poster and exhibit hall.

### LANGUAGE INFORMATION

All sessions at ISPOR 2019 are presented in English. ISPOR regrets that due to the disruption to other delegates, whisper translation (chuchotage) is not permitted in any session, including short courses. To discuss options to meet educational needs in multiple languages, please contact [conferences@ispor.org](mailto:conferences@ispor.org).

### COAT CHECK

You may check your coat, baggage, and/or poster with an attendant in the Coat Check Room, located in the lobby of Hall H of the convention center. Daily coat check fees are as follows: \$2.00 per coat and \$3.00 per bag/poster case. Cash and credit cards will be accepted.

### PRESENTATION SLIDES/POSTERS

Plenary session, issue panel, workshop, ISPOR forum, and symposia slides will be available via the conference app and at the ISPOR 2019 Released Presentations page at [www.ispor.org](http://www.ispor.org) during/after the conference, subject to speaker approval.

Podium and poster presentation abstracts and released slides or poster PDFs are available at the ISPOR Scientific Presentations Database (a searchable database of over 45,000 research papers presented at ISPOR conferences) at [http://www.ispor.org/research\\_study\\_digest/index.asp](http://www.ispor.org/research_study_digest/index.asp).

The Released Presentations page will feature many of the conference's slide presentations as PDFs. In 2018, more than 80% of the presentations were available to the public during/after the conference. The Released Presentations page is accessible via the conference mobile app and at [www.ispor.org/ISPOR2019-Released-Presentations](http://www.ispor.org/ISPOR2019-Released-Presentations).

### SPEAKER INFORMATION

**Upload the final version of your slide presentation in the Speaker Ready Room on the SAME day of your session!**

All speakers are encouraged to use the Speaker Ready Room to preview their slide presentations and/or upload an updated version. Presentations submitted to ISPOR Speaker's Corner by the specified advance deadline and all presentations uploaded/updated in the Speaker Ready Room 30 minutes prior to the session will be preloaded to the computer in the session room. All speakers are requested to arrive at their presentation room 15 minutes prior to the session start time. ISPOR staff will be available in the session room to assist the presenter.

A **Speaker Ready Room** is provided in Room 277 with the following opening hours:

- Sunday, May 19 12:00PM - 6:00PM
- Monday, May 20 8:00AM - 6:00PM
- Tuesday, May 21 8:00AM - 6:00PM
- Wednesday, May 22 8:00AM - 2:00PM

### ISPOR RESEARCH PRESENTATION AWARDS



Awards are given for the best research presentations for podiums and posters in the categories of GENERAL, NEW INVESTIGATOR, and STUDENT (up to 3 in each category). All research podium presentations are considered for an award. The top 10% of research poster presentations, based on abstract review score, are considered for a poster presentation award. These are identified with a rosette and will be judged during the conference. Award recipients will be notified by email and recognized on the ISPOR website at the conclusion of the conference.

### SOCIAL MEDIA

Communicating by way of social media is encouraged if it falls within embargo and communications rules.



**Be part of the live discussion!**

- Tweet your comments to @ISPORorg during the conference using #ISPORAnnual
- Access expert insights and share your views on conference sessions at the ISPOR LinkedIn Discussion Group: <http://bit.ly/ISPOR-Lin-Discussion>
- Network with your peers on the ISPOR Facebook page: <http://bit.ly/ISPOR-FB>

### RECORDING & PRESS INFORMATION

ISPOR supports the promotion of research presented at ISPOR conferences, while safeguarding sensitive information, data, and research findings that are not yet available to the public. **Due to the sensitive nature of data, particularly preliminary unpublished research findings, all filming and recording of scientific sessions and the poster hall is prohibited during the conference, without the express written consent of ISPOR.**

Portions of ISPOR 2019 may be recorded by ISPOR. By participating in the discussions, conference registrants agree that ISPOR may electronically copy, videotape, or audiotape their attendance at and involvement in any program. Registration and attendance at ISPOR 2019 constitutes an agreement by the registrant to ISPOR's use and distribution (both now and in the future) of their image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities. ISPOR will strictly enforce its rights as the exclusive licensee of all publication and reproduction rights to each presentation, and no presentation, in whole or in part, may be reproduced without approval from ISPOR.

Conference attendees must gain approval from a speaker or poster presenter prior to quoting or publishing that individual's scientific results. Members of the press must identify themselves as such before questioning speakers and congress attendees if using the information in a professional capacity.

More detailed information on ISPOR's Press Pass, Legal, and Embargo Policies are available on ISPOR's News & Press page at the ISPOR website ([www.ispor.org](http://www.ispor.org)).

**For further questions on these policies, please contact: Betsy Lane ([blane@ispor.org](mailto:blane@ispor.org)), Director and Chief Marketing & Communications Officer.**

### CONFERENCE PROGRAM DISCLAIMER

Please be advised that while the conference program is designed to provide accurate information regarding the subject matter covered, the views, opinions, and recommendations expressed are those of the authors and speakers, not of ISPOR, and thus ISPOR does not guarantee the accuracy of the information disseminated. If professional advice is desired, please consult a competent professional.

### ANTITRUST COMPLIANCE

It is the undeviating policy of ISPOR to comply strictly with the letter and spirit of all local and U.S. Federal, State, and applicable international trade regulations and antitrust laws. Any activities of ISPOR or ISPOR-related actions of its officers, Executive Committee Members, or members that violate these regulations and laws are detrimental to the interests of ISPOR and are unequivocally contrary to ISPOR policy.

### FINANCIAL DISCLOSURE INFORMATION

Research podium and poster presentation financial disclosure information will be available online only at: [https://www.ispor.org/valueinhealth\\_index.asp](https://www.ispor.org/valueinhealth_index.asp) in *Value in Health* (Volume 22, Suppl 1) in June 2019. Faculty and staff involved in the planning or presentation of this conference are required to disclose all real or apparent commercial financial affiliations related to conference content. This information is available on request at the ISPOR Registration desk.

### QUESTIONS & INFORMATION

Please ask ISPOR staff members for any additional information about the conference or about ISPOR. ISPOR staff can be identified by their ISPOR name badges.


## Conference Rooms Floor Plans

### THIRD FLOOR




### SECOND FLOOR

Please enter the New Orleans Theater from the Mid-Level, one level above the Second Floor.



### FIRST FLOOR



#ISPORAnnual  
NETWORK: **ISPOR2019**  
WI-FI PASSWORD: **HEALTHCORE**



## CALL FOR PAPERS

# Systematic Literature Reviews Related to Healthcare Treatments and Policies

# Value in Health

Systematic literature reviews are an essential component for obtaining data inputs or assessing the impact of health technologies on clinical, economic, or health-related quality of life. Systematic reviews may inform coverage decisions for drugs, devices, or public health interventions, and frequently are used in comprehensive health technology assessments. When conducted properly, systematic literature reviews pool all relevant data to allow a more efficient process for assessing value. Therefore, a full understanding of systematic reviews—and how to implement them in practice—is imperative for anyone involved in healthcare research, practice, and policy.

Recognizing the inherent usefulness of these types of studies, the Editors of *Value in Health* are issuing an open Call for Papers for systematic literature reviews on a wide array of topics that seek to inform healthcare decision making. Submissions do not need to focus solely on reviews of randomized controlled

trials; they can include reviews of observational studies, economic evaluations, outcomes research studies, and preference-based assessments. Reviews can address any aspect of value in health (eg, quality of life, resource use, and cost-effectiveness), but papers reporting reviews of studies containing only clinical endpoints are out of scope for this call.

Topics of interest include, but are not limited to:

- Systematic reviews of the value of drugs, devices, procedures, and other health technologies
- Evaluations that provide credible evidence of heterogeneity of treatment effects across comparator health interventions
- Systematic reviews of healthcare policies or the use of methods to assist policy making (eg, MCDA)
- Methodological articles that address bias or other techniques to produce comprehensive assessments

Submissions received before **November 15, 2019** will have the best chance of being published in *Value in Health* in 2020. Final decisions regarding ultimate acceptance rest solely with the Editors.

Authors should submit manuscripts through the journal's online submission system at <https://mc.manuscriptcentral.com/valueinhealth> and be sure to classify their submissions as Systematic Literature Reviews.

[www.ispor.org](http://www.ispor.org)

505 Lawrence Square Blvd South, Lawrenceville, NJ 08648

© 2019 ISPOR – The professional society for health economics and outcomes research.

 **ISPOR**  
Improving healthcare decisions